Home Blog

Vote for 2026 Young Pharmacist of the Year!

0

The race for the 2026 Pharmanews Young Pharmacist of the Year Award is now open, with five outstanding nominees vying for the prestigious recognition. The public is invited to participate in the online voting process to determine this year’s winner.

Established in 2018 by Pharmanews Ltd., the award is an annual initiative designed to spotlight young pharmacists whose work is making a remarkable difference in healthcare delivery, community and social development, innovation, and research and development.

Now in its eighth edition, the award continues to provide a platform for acknowledging the ingenuity, dedication and impact of young professionals contributing to the advancement of pharmacy practice and public health.

At the conclusion of the nomination exercise, five candidates who received the highest number of nominations were selected by the screening panel to proceed to the online voting stage. The candidate with the most votes will be declared the overall winner.

The winner will receive a cash prize and a commemorative plaque, while the first and second runners-up will also be rewarded with consolation prizes.

Your vote helps celebrate excellence and recognise the next generation of pharmacy leaders.

Voting Rules

Please note that VOTING STARTS on 18 November, 2026 and closes on 8 December 2026, at 12 noon.

You can only vote once. The system will prevent you from voting if you have voted before.

Votes with fake emails will be prevented or disqualified.

Your comments are highly welcome. However, comments do not count as vote cast.

HOW TO REGISTER AND VOTE

Click on the register button.

Register Login

Fill out the form with your details: Username, Email (valid), choose User Password and confirm the User Password.

Click on Submit (a confirmation link will be sent to your email)

Log in to your email, click on the link sent to you from Pharmanews

Log in to the Pharmanews site with your username and password if you are not redirected to the voting poll, click on Vote Now)

Click on the name of your preferred candidate to vote.

NOTE: Your email must be confirmed

Register Login

 

WHO to FG: Leverage local drug production for health security

0

–As NAPharm inducts 11 new Fellows, honours Emzor boss with Lifetime Achievement Award

Emzor Pharmaceuticals boss, Dr Stella Okoli,, flanked by NAPharm executives after receiving her Lifetime Achievement Award

The World Health Organisation (WHO) has called on the Federal Government to create an enabling environment for local pharmaceutical manufacturers to thrive as part of efforts to achieve national health security and reduce Nigeria’s dependence on imported medicines.

The global health agency identified reliable electricity supply, access to affordable financing and soft loans, and the availability of essential production materials as critical requirements for boosting local pharmaceutical manufacturing and strengthening the country’s medicine security.

WHO also underscored the importance of innovation, medicine sovereignty and sustainable healthcare, noting that pharmacy practice is strategic to achieving health security and universal health coverage through the local production, regulation, distribution and rational use of medicines and other health products.

WHO Representative and Head of Mission in Nigeria, Dr Pavel Ursu, stated this in his keynote address at the 2026 Annual General Meeting and Investiture of New Fellows of the Nigeria Academy of Pharmacy (NAPharm), held from 16 to 17 November,2026  at the Old Great Hall, College of Medicine, Idi-Araba, Lagos.

Speaking on the theme, “Pharmacy for National Health Security: Advancing Innovation, Medicine Sovereignty and Sustainable Healthcare,” Ursu, who was represented by Dr Akinola Fatiregun, said a nation that could not manufacture, test, regulate and rationally use its essential medicines remained vulnerable to external disruptions.

Executives of the Academy and newly inducted Fellows at the investiture ceremony on Tuesday.

“A nation that cannot make, test, regulate, and wisely use its own essential medicines is a nation whose health can be switched off from outside itself,” he said.

Reflecting on developments since the COVID-19 pandemic in 2020, the WHO representative highlighted how the crisis exposed the dangers of relying on a handful of companies and countries for the supply of essential medicines and other global public health commodities.

He challenged Nigerian pharmacists to harness their expertise and innovative capacity to develop affordable medicines that would meet the needs of the population.

While acknowledging some progress made by local pharmaceutical manufacturers, Ursu identified several challenges requiring urgent attention, including inadequate electricity supply, weak collaboration between academia and industry, and the need for local manufacturers to secure international prequalification to compete effectively in global markets.

He urged pharmacists in academia to publish research findings in platforms accessible to policymakers and complement their research with sustained advocacy.

Those in the pharmaceutical industry, he said, should pursue internationally recognised quality standards, noting that prequalification and Maturity Level 4 (ML4) status should serve as pathways to global competitiveness rather than mere achievements.

He also called on policymakers to ensure continuity in government policies, sustain incentives for local manufacturers, provide remuneration for pharmacy services and ensure that pharmacists remained actively involved in policy decisions affecting the sector.

Speaking on the investiture, NAPharm President, Prof. Lere Baale, said the exercise was designed to provide pharmacists with a platform to make significant contributions to the pharmaceutical sector and national development.

He challenged the newly inducted Fellows to deploy their expertise towards transforming the pharmaceutical industry and advancing the nation’s healthcare system.

“Today, you receive more than a title. You inherit an obligation. An obligation to defend scientific integrity, to mentor those coming behind you, to advance knowledge and professional standards, to speak courageously when public health is threatened, and to deploy your expertise in service of our nation and humanity.

“Let your fellowship become a platform for collaboration, mentorship, innovation and service. Do not merely wear this honour of fellowship. Let that honour define your actions,” he charged.

Baale also called on the Federal Government to recognise pharmaceutical development as a strategic national priority by increasing investments in research, innovation, manufacturing excellence and sustainable local production capacity.

Also speaking, NAPharm Vice-President, Pharm. Ahmed Yakasai, said the investiture was an opportunity to celebrate integrity, knowledge and professional excellence among pharmacists.

He explained that the Academy’s selection process went beyond academic and professional achievements to assess the character and integrity of prospective Fellows.

According to him, a screening committee was constituted to evaluate candidates, leading to the selection of 11 pharmacists for the investiture.

Yakasai urged pharmacists to intensify efforts to combat fake and substandard medicines through improved pharmacovigilance, stronger professional standards and greater collaboration across the pharmaceutical supply chain.

The newly inducted Fellows are:  Pharm. (Dr) Shakirat Adeosun; Dr Solomon Aigbavboa; Pharm. Ignatius Anukwu; Pharm. (Dr) Josephine Ehimen; Pharm. (Dr) Bankole Ezebuilo; Pharm. Rasheed Faworaja; Pharm. (Dr) Ukamaka Okafor; Prof. Henry Okeri; Prof. Ogboona Okorie; Prof. Ibrahim Oreagba; and Pharm. (Dr) Titilayo Onedo.

In recognition of their contributions to pharmacy and national development, the Academy also honoured distinguished individuals with special awards.

The Chief Executive Officer of Emzor Pharmaceuticals, Pharm. (Dr) Stella Okoli, received the Lifetime Achievement Award in recognition of her contributions to the pharmaceutical industry, including the establishment of a multi-million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility aimed at strengthening Nigeria’s pharmaceutical independence.

Prof. Fola Tayo received the Distinguished Service Award for his contributions to pharmacology and service to the Academy as a foundation member.

The Honorary Fellowship Award was conferred on the Executive Chairman of Greenlife Pharmaceuticals Limited, Dr Obiora Chukwuka, and the Founder and Group Chief Executive Officer of A.A. Rano Group, Alhaji Auwalu Abdullahi Rano.

Congratulating the new Fellows, the President of the Pharmaceutical Society of Nigeria (PSN) urged them to justify the honour through measurable contributions to society and national development.

He also reminded them of their financial obligations to the Academy and the PSN, stressing that membership dues were essential to sustaining the organisations.

“You cannot be ordinary pharmacists from today. Let it not be heard that you refuse to pay your dues, both at the Academy and PSN. And if you have defaulted, go and quickly pay all the backlog of your dues, because whatever it is, that is the money we use to sustain these organisations,” he said.

In her response, the Lifetime Achievement Award recipient, Dr Okoli, expressed appreciation to the Academy for the recognition and urged pharmacists to remain committed to local pharmaceutical production as a pathway to achieving national medicine security.

“Quote me anywhere: Nigeria is the best country in the world. Nobody should feel sorry that they are Nigerians. The only thing we have to do is push hard,” she said.

 

National Health Council records 55% implementation of previous resolutions

0
National Health Council records 55% implementation of previous resolutions
The 67th National Council on Health brings together health leaders and stakeholders to advance Nigeria’s healthcare system and strengthen collaboration towards better health outcomes.

The 67th National Council on Health (NCH) Technical Session has opened in Lafia, Nasarawa State, with a review showing that 55 per cent of resolutions reached at its 66th meeting have been implemented.

The two-day session, which began on November 16, 2026, brings together health sector leaders to assess progress made on previous decisions and consider ways to improve healthcare delivery across the country.

Speaking at the opening ceremony, Nasarawa State Deputy Governor, Dr Emmanuel Akabe, urged delegates to develop practical resolutions that would translate policy commitments into measurable improvements in healthcare services.

He also appreciated the Federal Ministry of Health and Social Welfare for choosing Nasarawa State to host the national meeting.

Presenting the implementation report, the Director of Health Planning, Research and Statistics, Dr John Ovuoraye, said all 36 states and the Federal Capital Territory had submitted reports on the 20 resolutions reached at the previous council meeting.

According to him, 15 of the resolutions had recorded at least 50 per cent implementation, while 16 states achieved an implementation rate of 60 per cent or higher.

The Comprehensive Emergency Obstetric and Newborn Care Programme recorded the highest implementation rate of 69.3 per cent, followed by the NHSRII Emergency Preparedness and Response Plan at 67.7 per cent.

However, five resolutions covering sodium reduction, community cardiopulmonary resuscitation (CPR), larval source management, cosmetics safety and quality improvement remained below 50 per cent implementation.

Ovuoraye also identified gaps in accountability, noting that only 412 of the 740 expected state-level reports had been received, representing 56 per cent.

He recommended assigning specific officials to oversee each resolution, setting implementation timelines and introducing quarterly progress reports to improve accountability.

He further called for stronger technical support for states and the inclusion of council resolutions in their 2027 budgets and annual operational plans.

In her address, the Permanent Secretary of the Federal Ministry of Health and Social Welfare, Daju Kachollom S, said the technical session would review the previous council’s resolutions, examine memoranda submitted by states and other government agencies, and develop recommendations for the main council meeting.

She urged participants to focus on evidence-based recommendations and practical measures that would improve implementation.

The main council meeting is scheduled to hold from 19 to 20 November 2026, under the chairmanship of the Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate.

Also speaking, Nasarawa State Commissioner for Health, Dr Gwamna Gaza, reaffirmed the state’s commitment to ensuring a successful council meeting.

The National Council on Health is Nigeria’s highest health policy-making body. Its 67th meeting is expected to build on previous decisions and address implementation gaps through stronger collaboration between the federal and state governments.

 

Translate AMR pledges into action, WHO charges countries

0

Translate AMR pledges into action, WHO charges countries

The World Health Organisation (WHO) has urged countries to translate global commitments on Antimicrobial Resistance (AMR) into funded, measurable actions, warning that inadequate financing, weak surveillance and poor coordination are slowing progress.

Dr Jean-Pierre Nyemazi, director a i. of WHO’s Department of AMR, made the call at the sixth Global Media Forum webinar on AMR, on Monday, ahead of the 2026 World AMR Awareness Week (WAAW).

The WAAW, scheduled for 18 Nov. to 24 Nov., has the theme: “One Health, One Action: Prevent AMR Now”.

Nyemazi, who’s also director, Quadripartite Joint Secretariat on AMR, said bacterial AMR was associated with more than 4.7 million deaths globally in 2021.

He described the challenge as an urgent global health threat and development concern.

“AMR is one of the most urgent global health threats and development challenges.
“It threatens our ability to treat infections, protect animal and plant health, and produce safe food, and also has an impact on the environment,” he said.

He said world leaders, through the 2024 United Nations General Assembly Political Declaration on AMR, committed to reducing bacterial AMR-associated deaths by 10 per cent by 2030, from the 2019 baseline of 4.95 million.

They also pledged to ensure that at least 60 per cent of countries had funded national AMR action plans by 2030 and mobilise at least 100 million dollars in catalytic funding.

“However, let’s be honest. The gap between commitments and pledges versus implementation remains wide,” Nyemazi said.

He identified limited financing, fragmented coordination and weak surveillance systems as major obstacles.

He said the updated Global Action Plan on AMR for 2026 to 2036 had been finalised to strengthen implementation of the global commitments.

Dr Kefas Samson, WHO senior technical officer and lead of Multisectoral Coordination, AMR Department, described the updated plan as a renewed framework for translating global commitments into measurable country-level action.

“It is not just a plan, but a framework that translates the aspirations and ambitions of the 2024 Political Declaration on AMR into tangible actions at the country level,” he said.

Samson identified inadequate financing, gaps in nationwide AMR surveillance, weak infection prevention in healthcare facilities, limited diagnostic capacity and unequal access to quality-assured antimicrobials as persistent challenges.

According to him, the 2030 targets include ensuring that 70 per cent of antibiotics used in human health belong to the WHO Access Group and that 80 per cent of countries can test for priority bacterial and fungal pathogens.

On the role of the agricultural sector, Dr Junxia Song, deputy chief veterinarian and chief of the One Health and Disease Control Branch of the Food and Agriculture Organisation of the United Nations (FAO), said antibiotic use in livestock could increase by nearly 30 per cent by 2040 without intervention.

She said improved animal health and farm management practices could, however, reduce antibiotic use by up to 57 per cent.
“Prevention must become central to the global fight against AMR, with farmers placed at the heart of the response,” Song said.

She said FAO’s 10-year initiative, Reduce the Need for Antimicrobials on Farms (RENOFARM), was promoting better animal health services, production practices, alternatives and innovation, incentives and partnerships.

Song said more than 400 partners, including over 80 FAO member countries, were engaged in the initiative.

Aitziber Echeverria, AMR coordinator, Chemicals and Health Branch of the United Nations Environment Programme (UNEP), said environmental pollution was a major factor in the emergence, transmission and spread of AMR.

“The environment plays a key role in the emergence, transmission and spread of AMR. The environment and AMR cannot be treated separately. That is the One Health concept,” she said.

Echeverria identified pharmaceutical manufacturing, agriculture and food systems, healthcare facilities, and municipal waste and wastewater management as priority areas requiring intervention.

She called for stronger environmental surveillance, wastewater treatment, safe disposal of antimicrobials and the integration of environmental authorities into national AMR coordination structures.

“Environmental action on AMR is not an optional addition to the response. It is a prerequisite for success,” she said.

Similarly, Dr Jane Lwoyero, Programme Officer at the World Organisation for Animal Health (WOAH), called for increased investment in animal health systems, vaccination, farm biosecurity and veterinary services to reduce infections and antimicrobial use.

She said animal diseases caused estimated annual losses of up to 300 billion dollars globally, while prevention offered significant economic benefits.

“For every one dollar that is invested in prevention of animal diseases and for better animal health systems, we are ensured of getting a return of 28 dollars,” Lwoyero said.

She also called on countries to discontinue the use of antimicrobials for growth promotion in animals, noting that countries permitting the practice used 45 per cent more antimicrobials than those that did not.

The Chairperson of the Global AMR Media Alliance (GAMA), Shobha Shukla, urged journalists to sustain public awareness of AMR and promote responsible use of medicines.

“The central challenge is no longer simply getting countries to recognise AMR or develop national action plans.

“It is ensuring that countries have the funding, surveillance systems, laboratory capacity, effective interventions and accountability mechanisms to implement them,” she said.

Shukla said the media had an important role in humanising AMR and explaining its implications for people, animals, plants and the environment.

NAN reports that the Fifth Global High-Level Ministerial Conference on AMR, scheduled to hold in Abuja from Dec. 6 to Dec. 8, would review progress, address implementation challenges and renew political commitment. (NAN)

Risikat Lawal wins 2026 Biogenerics  Community Pharmacy Integrity Award

0

 

Pharm. Risikat Bolanle Lawal, the award winner , and  Pharm. (Dr) brahim Kolawole Bello, retired director, University of Ilorin Teaching Hospital, Ilorin, Kwara State

Pharm. Risikat Bolanle Lawal, the award winner, and  Pharm. (Dr) Ibrahim Kolawole Bello, retired director, University of Ilorin Teaching Hospital, Ilorin, Kwara State

Pharm. Lawal has emerged as the winner of the 2026 Biogenerics Community Pharmacy Integrity Award at the 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN), tagged IJELE 2026, held from 2–7 November 2026 at the International Convention Centre, Awka, Anambra State.

The award was formally presented at the conference’s Closing Dinner,  in recognition of her contributions to community pharmacy practice, professional leadership and healthcare delivery, and included a cash prize of N500, 000. and a certificate.

The Biogenerics Community Pharmacy Integrity Award, established by the Pharmaceutical Society of Nigeria in partnership with Biogenerics Nigeria Limited, recognises pharmacists who demonstrate professional integrity, excellence and commitment to advancing community pharmacy practice.

Pharm. Lawal is an experienced pharmacist with extensive service in public-sector pharmaceutical administration and community pharmacy. 

She served as Director of Pharmaceutical Services, Kwara State Ministry of Health, from 2011 to 2018. She also served as Chairperson of the Association of Lady Pharmacists (ALPS), Kwara State Branch, from 2007 to 2010. She was also Chairperson of Hospital Pharmacists, Kwara State, from 1993 to 1999.

A graduate of the University of Ife (now Obafemi Awolowo University), where she obtained her Bachelor of Pharmacy degree in 1981, she holds a postgraduate qualification from the West African Postgraduate College of Pharmacists, a Master’s degree in Public Health from the University of Ilorin and a Certificate in Health Management and Planning.

Beyond her public-sector service, she has participated in immunisation programmes and community health outreaches. She currently practises at Reese Pharmacy, GRA, Ilorin, Kwara State.

Her emergence as the 2026 recipient celebrates her sustained contributions to the pharmacy profession and reinforces the importance of integrity, professional commitment and quality service in community pharmacy practice.

Okeroghene Timipre wins 2026 Biogenerics Hospital Pharmacy Integrity Award

0

 

The Award winner flanked by dignitaries at the presentation of the certificate and dummy cheque.

A newly appointed Consultant and Clinical Pharmacist at the Federal Medical Centre, Yenagoa, Bayelsa State, Dr Okeroghene Aghogho Timipre has emerged as the winner of the 2026 Biogenerics Hospital Pharmacy Integrity Award.

She was announced the winner of the award at the closing banquet of the 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN), tagged IJELE 2026, held from 2–7 November 2026 at the International Convention Centre (ICC), Awka, Anambra State.

The award, which comes with a plaque and certificate, also has a N1 million prize tag.

While speaking during the presentation of the award, a former President of PSN, Pharm Yaro Budah commended the award winner for her contributions to the pharmacy profession. The ex-PSN president said, “Integrity attached to the award is virtue; I commend you for the display of integrity in the public hospital, especially this period when integrity has become a scarce commodity”.

The Biogenerics Hospital Pharmacy Integrity Award for Pharmacists in Public Hospitals was established by the Pharmaceutical Society of Nigeria (PSN) in partnership with Biogenerics Nigeria Limited to promote professional integrity, ethical standards and commitment to excellence among pharmacists in public hospitals, with the broader goal of enhancing patient care and healthcare delivery in Nigeria.

The 2026 application process required candidates to provide documented evidence of their academic and professional qualifications, leadership positions, career achievements, innovations, professional and academic performance, research, publications and contributions to society.

Applicants were also required to submit a statement explaining why they deserved the award, supporting documents and recommendations from three Fellows of the Pharmaceutical Society of Nigeria.

Dr Timipre is a clinical pharmacist with specialisation in Critical Care and Specialised Nutrition Support and a recently appointed Consultant Pharmacist at the Federal Medical Centre (FMC), Yenagoa, Bayelsa State. Prior to her recent appointment, she served as an Assistant Director of Pharmacy at the institution.

She also holds an academic appointment as Adjunct Lecturer I in the Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Niger Delta University (NDU), Wilberforce Island, Amassoma, Bayelsa State.

Her academic qualifications include a Bachelor of Pharmacy (B.Pharm) degree, Doctor of Pharmacy (PharmD) degree and a Master’s degree in Clinical Pharmacy and Pharmacy Practice. She is a Fellow of the West African Postgraduate College of Pharmacists (WAPCP), Faculty of Clinical Pharmacy, with specialisation in Critical Care and Specialised Nutrition Support. She is currently pursuing a PhD in Clinical Pharmacy and Pharmacy Practice at the Niger Delta University, Wilberforce Island, Amassoma, Bayelsa State.

Her professional practice spans hospital pharmacy, critical care, specialised nutrition support, clinical pharmacy education, research and professional service.

At the Federal Medical Centre, Yenagoa, she has helped develop clinical pharmacy practice through initiatives that strengthen pharmacists’ participation in direct patient care.

Notably, she initiated intensive care unit (ICU) ward rounds at the facility. She introduced structured pharmacy-only ward rounds to encourage clinical discussions among pharmacists on the pharmaceutical care needs of admitted patients.

Her contributions also extend to pharmacy education and professional mentorship. Through her academic appointment at the Niger Delta University, she contributes to the teaching of pharmacy students across different year groups and provides clinical exposure to final-year pharmacy students through facility-based ward-round preceptorship at FMC Yenagoa.

Beyond her clinical and academic responsibilities, Dr Timipre is actively involved in professional pharmacy leadership. She currently serves as the National Publicity Secretary of the Clinical Pharmacists Association of Nigeria (CPAN). In December 2025, she was appointed by the Pharmaceutical Society of Nigeria as the National Unofficial Member of the Executive Committee of the Association of Consultant Pharmacists of Nigeria (ASSCOP).

Her application for the award was supported by three distinguished Fellows of the Pharmaceutical Society of Nigeria, namely Prof. Joshua Funsho Eniojukan; Pharm. (Dr) Austin Osamwonyi Onabor, and Pharm. (Dr) Alek Okunbriowei.

Reacting to the recognition, Dr Timipre expressed gratitude to God Almighty for the honour and acknowledged the support of her mentors, colleagues, family and the wider pharmacy community. She described the award as an important professional milestone and a motivation to deepen her contributions to patient care, clinical pharmacy practice, professional education and the advancement of the pharmacy profession.

 

 

NUJ moves to secure health insurance for Lagos journalists

0

NUJ moves to secure health insurance for Lagos journalists

 

The Nigeria Union of Journalists (NUJ), Lagos State Council, has set up a five-member committee to develop strategies for including journalists in the implementation of the state’s mandatory health insurance policy.

The committee, constituted by the newly elected council chairman, Comrade Adewale Akodu, will prepare a position paper outlining how journalists across different media organisations can access affordable and sustainable health insurance coverage.

The move follows the council’s commendation of Governor Babajide Sanwo-Olu for introducing mandatory health insurance for Lagos residents, describing the policy as a significant step towards improving healthcare access and reducing the financial burden of medical expenses.

Under the policy, residents, employers and workers are expected to obtain health insurance coverage by December 31, 2026, ahead of full enforcement on January 1, 2027.

According to the council, the implementation of the policy must consider the peculiar working conditions of journalists, including those in print, broadcast and online media, as well as freelance practitioners.

The five-member committee comprises Vivian Ihechu of the News Agency of Nigeria (NAN), Julie Ekong of Radio Nigeria, Aminat Elegushi of Lagos Television (LTV), Aderayo Idowu-Olaiya of Lagos Traffic Radio and Olawale Afolabi of the Lagos State Ministry of Information and Strategy.

The committee is expected to examine the financial realities of journalists, their welfare needs and the responsibilities of media employers and employees under the policy.

It will also explore possible partnerships involving the NUJ, Lagos State Government, Lagos State Health Management Agency (LASHMA), accredited Health Maintenance Organisations (HMOs) and media organisations to ensure accessible and affordable coverage for media practitioners.

The council said the proposed position paper would serve as a basis for engagement with government agencies, media owners and other stakeholders to ensure journalists are not excluded from the policy’s implementation.

It further urged media organisations, employers and journalists to begin preparations to secure appropriate health insurance plans before the December deadline.

The council maintained that journalists, whose work involves informing the public and holding institutions accountable, deserve access to quality healthcare, adding that their well-being is essential to the productivity and sustainability of the media industry.

The statement was signed by Akodu and the council’s secretary, Olayide Awosanya.

Substantiate your allegations, PCN challenges Kano task force chair

0

 

Substantiate your allegations, PCN challenges Kano task force chair

The Pharmacy Council of Nigeria (PCN) has challenged the Chairman of the Kano State Multi-Agency Taskforce on Drug Abuse and Illicit Trafficking, Muhuyi Magaji Rimin Gado, to substantiate allegations that the agency is shielding drug dealers and facilitating the distribution of illicit substances in Kano State.

Describing the allegations as baseless, the PCN, in a rebuttal signed by Pharm. Hasiya Ladan, Consultant Pharmacist at its Kano State Office, urged Gado to provide evidence to support his claims of misconduct against some of its personnel, stressing that it takes allegations of staff misconduct seriously.

At a press conference , Gado had questioned the circumstances surrounding the issuance of import licences to pharmaceutical companies dealing in pregabalin, particularly following its rescheduling as a controlled drug by the National Agency for Food and Drug Administration and Control (NAFDAC) on September 14, 2026.

He further alleged that the PCN “facilitated these unlawful activities by registering No. 10 Apple Avenue, a purely residential area to serve as a concealed outlet that has been used contrary to the provision of the Land Use Act, and which has been used as a means for distribution of this product to our streets. By doing so, the PCN has compromised the entire rationale of CWC which they advocate.”

The task force chairman also claimed that “Task force investigation reveals that some staff of the PCN engaged deeply in these types of clandestine business which explains why they are over protective and always want to be exclusive…”

He further alleged that the PCN had fewer than 20 staff members in Kano but continued to insist that it had exclusive powers to seal pharmaceutical premises, even when wrongdoing was uncovered.

Responding to the allegations, the PCN said its exclusive regulatory authority over pharmaceutical premises had been established by the Constitution and affirmed by the Supreme Court in Pharmacists Board of Nigeria v. Franklin Adegbesote (1986) 5 NWLR (Pt. 44) 707, SC 68/1986. It also cited a Federal High Court judgment in Kano in Suit No. FHC/KN/CS/152/2023 (16 February 2024), National Assembly resolutions of 2018 and 2025, and a letter dated March 28, 2001, by the then Attorney General of the Federation and Minister of Justice, Chief Bola Ige, SAN, to the Attorney General/Commissioner for Justice, Rivers State.

“This exclusive right is not in doubt, as the Chairman, being a lawyer, should be familiar with some of the institutions and instruments mentioned here,” the Council stated.

Ladan also dismissed Gado’s claims about the PCN’s alleged lack of regulatory capacity, describing them as evidence of ignorance of the Council’s regulatory framework.

“For emphasis, the regulatory framework or structure for recommendation for approval and licensing of premises is robust and is well established in the 36 states of the Federation and the FCT, with appropriate legal framework,” she stated.

She explained that the PCN had established two committees in every state: the Pharmaceutical Inspection Committee (PIC) and the Patent and Proprietary Medicines Vendors Licence Committee (PPMVLC). Both committees are chaired by the Directors of Pharmaceutical Services (DPSs) in the respective State Ministries of Health, who represent the interests of state governments.

According to her, each PSN State Chairman serves as vice-chairman of the committees, while PCN officers and other experienced and credible pharmacists appointed within the states serve as inspectors.

“It is this structure that inspects and recommends for approval all facilities for licensure. For emphasis, the PCN Officer-in-Charge only serves as Secretary to the two committees and also provides secretariat services,” she explained.

Ladan maintained that the Council’s ability to discharge its regulatory responsibilities was not determined by the number of its personnel in Kano, noting that it could mobilise the required human resources whenever necessary.

She added that the PCN’s regulatory capacity had been affirmed by the World Health Organisation (WHO) during its Global Benchmarking of Nigeria for Maturity Level 3, noting that PCN and NAFDAC were the only national regulatory authorities in Africa to have achieved and retained the global ranking.

On the issuance of import licences and product permits, the Council clarified that while the PCN is responsible for issuing import licences to importing companies, NAFDAC is responsible for issuing product permits specifying the categories and quantities of products to be imported.

“Except there is evidence of illegal distribution of the drug from the said premises, the Chairman cannot allege any wrongdoing,” Ladan stated.

Addressing the allegation that the PCN had registered a pharmaceutical outlet in a residential area in violation of the Land Use Act, the Council faulted Gado for failing to identify the specific provisions of the Act allegedly breached.

It explained that its Pharmaceutical Premises Location, Inspection, Structure, Monitoring and Enforcement Regulations, 2022 stipulate the requirements for the registration and location of pharmaceutical premises.

“Whether a facility allocated for residential purposes can be used for the sale of medicines or any pharmaceutical product is not for the Pharmacy Council of Nigeria to decide. This is not one of the issues that is taken into consideration in determining an application for location approval.

“The law does not restrict or prohibit the registration of pharmaceutical premises in residential areas. Therefore, both residential and commercial areas are, by the Act, eligible for registration, provided they meet other requirements of the law,” Ladan stated.

ACPN secretariat must be  a centre of action not just an office — Ikwu

0

 

ACPN secretariat must be  a centre of action not just an office — Ikwu
Pharm. Obiageri Ikwu

 

Effective leadership of a professional association requires efficient administration, timely communication and a commitment to serving members. For the Association of Community Pharmacists of Nigeria (ACPN), these are important priorities as practitioners confront challenges in sustaining their businesses and adapting to changes in healthcare delivery. In this interview with Adebayo Oladejo, Pharm. Obiageri Ikwu, the newly elected national secretary of ACPN, speaks on her emergence at the association’s last national conference in Abuja. She also highlights her INNOVATE2EXCEL agenda, the challenges facing community pharmacy and the need for a more responsive secretariat. Excerpts:

 

What does your emergence as ACPN national secretary mean to you?

It is both an honour and a call to service. I am grateful to God and ACPN members for the confidence they have placed in me. I see the position as an opportunity to contribute to the growth of the association and the advancement of community pharmacy practice in Nigeria.

Through my INNOVATE2EXCEL agenda, I hope to build a more efficient, transparent, responsive and united ACPN, with a secretariat that serves as a one-stop centre for members through improved communication, proper documentation, inclusion and timely implementation of decisions.

 

How has your professional experience prepared you for the role?

My experience in community pharmacy has taught me empathy, problem-solving and the importance of listening to people. My previous service within ACPN, particularly as national financial secretary, also strengthened my understanding of accountability, documentation and effective communication.

These experiences have prepared me for the administrative and leadership responsibilities of the office. I believe effective leadership requires diligence, collaboration and a willingness to listen to members while ensuring transparency in decision-making.

 

What are the biggest challenges facing community pharmacy in Nigeria?

Major challenges include the sustainability of community pharmacies, regulatory issues, access to quality medicines, professional development and the changing healthcare environment. These concerns require deliberate efforts to protect practitioners’ interests while ensuring that patients receive safe and effective pharmaceutical care.

ACPN must respond through sustained advocacy, member empowerment, stakeholder engagement and professional development. We must also support initiatives that make community pharmacies more sustainable and better equipped to meet Nigerians’ evolving healthcare needs.

 

How can pharmacists remain relevant in the age of AI and digital health?

Pharmacists must embrace change and move beyond dispensing medicines to provide broader pharmaceutical care. Health education, screening, vaccination and other appropriate clinical services offer opportunities to make greater contributions to patient care and public health.

Technology and artificial intelligence can improve efficiency, but they should not replace professional judgement or the human side of healthcare. Pharmacists must continue to develop their skills and use innovation to improve patient outcomes while maintaining professional standards.

 

How can Nigeria stem the migration of pharmacists?

We must create an environment where pharmacists can build rewarding careers in Nigeria. This requires better professional development opportunities, sustainable pharmacy practice, mentorship and career pathways that allow young pharmacists to grow and contribute meaningfully.

We should not simply ask young pharmacists to stay; we must help create conditions that make staying and building a career here worthwhile. Professional associations, government and other stakeholders all have roles to play in making the practice environment more supportive and attractive.

 

What changes do you plan to introduce to ACPN’s administration?

My INNOVATE2EXCEL agenda emphasises an efficient, responsive and digitally driven Secretariat. We want to strengthen documentation, improve information dissemination, enhance communication with state chapters and ensure that important decisions and activities are properly recorded.

We have also started a monthly newsletter to disseminate information to community pharmacists across Nigeria and keep members informed about ACPN activities and relevant developments. Information should not get lost, and members should not be left wondering what is happening within their association.

 

What message does your emergence send to women in Pharmacy?

Women have an important place at every level of pharmacy leadership. My advice to young women is to prepare themselves, remain teachable, build meaningful relationships and develop the competence required to take on greater responsibilities.

Leadership requires commitment, integrity and accountability. Women can lead with empathy while remaining decisive and firm. I encourage aspiring female leaders to believe in their abilities, continue learning and seize opportunities to contribute meaningfully to the profession.

 

What legacy do you hope to leave in ACPN?

I want members to look back and say that the secretariat worked better because of the efforts we made during our tenure. I hope to contribute to better communication, stronger documentation, greater digital efficiency and more inclusive engagement with members.

These improvements should become sustainable systems that continue to serve ACPN beyond any individual’s tenure. If members can say, “We were informed, included, heard and ACPN moved forward,” I would consider that a meaningful contribution.

Empower pharmacists to drive Nigeria’s healthcare transformation, expert says

0

 

– As Ogun NAIP distributes free medicines to mark World Pharmacists Day

Empower pharmacists to drive Nigeria’s healthcare transformation, expert says
L-R: Superintendent Pharmacist, Geneith Pharmaceutical Ltd, Pharm. Uzokwe Obianuju; Deputy Managing Director, Drugfield Pharmaceuticals Nigeria Ltd., Dr Olabode Ekundayo; Head, Plant Operation and Superintendent Pharmacist, Shalina Healthcare Nigeria Ltd., Dr Lawrence Agada; Regulatory Affairs Manager, Emzor Pharmaceutical Industries Ltd., Pharm. Colette Okwuchi; Chairman of NAIP Ogun Zone, Pharm. (Mrs) SarahPearl Kolade and PANS President, OOU, Mr Onifade Bolaji, at the occasion marking the World Pharmacists Day by NAIP, Ogun State  Zone.

 

Pharmacists must be equipped with the right skills, knowledge and working environment to play a greater role in transforming Nigeria’s healthcare system, an expert in the pharmaceutical sector has said.

The call was made at the World Pharmacists Day celebration organised by the Ogun State Zone of the Association of Industrial Pharmacists of Nigeria (NAIP), where discussions focused on the need for pharmacists to expand their competencies and contribute beyond their traditional role of dispensing medicines.

The event, which featured the distribution of free medicines to residents of Sango-Ota, also highlighted the vital role of pharmacists in healthcare delivery and the importance of continuous professional development in meeting the evolving demands of the health sector.

Delivering the keynote address, the Head of Plant Operations and Superintendent Pharmacist at Shalina Healthcare Nigeria Limited, Dr Lawrence E. Agada, said the theme of the 2026 World Pharmacists Day, “Empowering Pharmacies for a Healthier Future”, was particularly relevant at a time when the profession is increasingly being challenged to demonstrate its broader value to the healthcare system.

Agada noted that pharmacists receive training in diverse fields, including pharmacology, pharmaceutics, pharmaceutical chemistry, pharmaceutical microbiology, healthcare and law. However, he stressed that this broad-based training must translate into greater impact on healthcare delivery.

He urged pharmacists to look beyond dispensing medicines and develop the depth of knowledge and professional competence required to address wider healthcare challenges.

“We are talking about empowering pharmacists, and empowering pharmacists means equipping them with the competencies, recognition and working environments necessary to meet evolving health needs,” he said.

According to him, empowerment should enable pharmacists to apply their knowledge and skills to solving healthcare problems rather than limiting themselves to routine professional functions. He explained that pharmacists need to understand not only the medicines they dispensed or manufactured but also the science, research and processes underpinning their development and production.

Agada said this is particularly important in industrial pharmacy, where professionals needed a sound understanding of pharmaceutical manufacturing processes, product development and quality assurance.

He encouraged pharmacists to embrace continuous learning, noting that professional development should extend beyond formal academic qualifications.

“Education goes beyond just academics, though it includes academics. It includes international forums like this,” he said, adding that professional gatherings provided opportunities to acquire knowledge and insights that might not be readily available within academic institutions.

The Shalina Healthcare executive also emphasised the importance of professional competencies, describing them as a combination of skills, knowledge, attitudes and behaviours needed to discharge professional responsibilities effectively.

He urged younger pharmacists to cultivate a habit of learning and develop a genuine interest in understanding the principles and processes underlying pharmaceutical practice and manufacturing.

Drawing on his professional experience, Agada explained that his career progression from community pharmacy to pharmaceutical sales and eventually manufacturing has been driven by his desire to deepen his understanding of medicines and pharmaceutical processes.

He advised pharmacists not to focus solely on passing examinations or obtaining qualifications but to strive to understand and apply the knowledge they acquired.

“It’s not about you just passing an exam. It’s about you understanding and carrying and living with the knowledge that you keep building up,” he said.

Also speaking at the event, the Deputy Managing Director of Drugfield Pharmaceutical Nigeria Limited, Dr Olabode Ekudayo, urged pharmacists to remain curious and committed to learning, describing curiosity as an essential driver of professional growth.

He observed that pharmacists who consistently asked questions and sought deeper understanding would be better positioned to identify knowledge gaps, acquire new skills and improve their contributions to healthcare delivery.

Ekudayo encouraged practitioners to broaden their knowledge and remain open to learning as the profession evolved.

“Pharmacists should be curious. Curiosity will push you to want to know more, and many things. It will push you to learn, and know what you need to know,” he said.

Earlier, the Chairman of NAIP Ogun Zone, Pharm. (Mrs) Serah-Pearl Kolade, urged pharmacists to sustain their commitment to professional growth and continually equip themselves with relevant knowledge and skills.

She encouraged practitioners to take personal responsibility for their development by pursuing learning opportunities and strengthening their capacity to contribute meaningfully to the healthcare system.

Kolade also urged pharmacists to remain committed to the profession and uphold its values and standards to advance pharmacy practice.

Beyond the professional discussions, the celebration provided an opportunity for NAIP Ogun Zone to extend its activities to the wider community.

As part of the programme, the association distributed free over-the-counter (OTC) medicines to residents of Sango-Ota and educated community members on the dangers of drug abuse.

A patient taking erythromycin develops an unusually high plasma concentration

6

A patient taking erythromycin develops an unusually high plasma concentration

1. A patient taking erythromycin develops an unusually high plasma concentration of a concurrently administered drug that is primarily metabolised by CYP3A4. What best explains this interaction?
A. Increased plasma protein synthesis
B. Induction of CYP3A4 activity
C. Inhibition of CYP3A4 activity
D. Activation of renal drug secretion

2. A drug exhibits a narrow therapeutic index and undergoes extensive first-pass metabolism. Which route of administration most directly avoids hepatic first-pass metabolism while still allowing systemic absorption?
A. Rectal administration
B. Intraperitoneal administration
C. Oral administration
D. Sublingual administration

Afonchies offers free diabetes, blood pressure screening in Ajah

0
Participants at the screening exercise

In commemoration of the 2026 World Diabetes Day, Afonchies Pharmacy Limited has offered free blood glucose and blood pressure screening to residents of Addo, Badore, Langbasa and neighbouring communities in the Ajah area of Lagos State.

World Diabetes Day is observed annually on 14 November to raise awareness about diabetes and promote prevention, early diagnosis and effective management. According to the International Diabetes Federation, approximately 24.6 million adults aged 20–79 were living with diabetes in Africa in 2024, with nearly three out of four unaware of their condition.

The screening exercise, held on Saturday, 14 November, at the company’s Addo branch, targeted 200 adults and aligned with this year’s theme, “Early Action on Diabetes,” which emphasises early diagnosis and timely intervention to prevent complications. In addition to the free blood glucose and blood pressure checks, participants received health counselling and professional medication advice.

The Managing Director of Afonchies, Pharm. Adebayo Afon, said the initiative reflected the company’s commitment to making healthcare more accessible and encouraging people to take greater responsibility for their health through regular screening and early intervention.

He explained that the company’s community pharmacy model went beyond dispensing medicines to providing health education, identifying potential health risks and connecting people to appropriate care. He also emphasised the importance of community-based interventions in addressing the burden of undiagnosed diabetes and hypertension.

Speaking on the activities at the screening centre, the Chief Pharmacist representing the Addo branch, Pharm. Michael Akpala, said the exercise was designed to address the fear and cost that often discourage people from checking their blood sugar and blood pressure.

He disclosed that beneficiaries with concerning results would receive counselling and be linked to nearby primary healthcare facilities, including those in Addo and Badore, for further evaluation and care. He added that the company hoped to build on the initiative by encouraging regular health checks.

Also speaking, the Chief Operating Officer, Pharm. Oluwatosin Majoyeogbe, disclosed that Afonchies currently had 13 active branches, with another nearing completion. He said the company intended to make the screening programme an annual event, rotating it across different communities where it operates.

He described community pharmacies as the first point of healthcare contact for many residents, stressing their role in promoting medication safety and appropriate treatment.

One of the beneficiaries, 78-year-old elder statesman, Mr Samuel Akinrinifin, commended Afonchies for the initiative, describing it as a valuable opportunity, particularly for elderly residents, to monitor their health.

Akinrinifin, who said regular health checks had been part of his personal healthcare routine, expressed satisfaction with the exercise, adding that he had never been hospitalised because of his commitment to regular monitoring. He urged Afonchies and other healthcare providers to sustain such initiatives and extend them to more elderly people.

 

HCPAN seeks equitable tariffs, stronger LASHMA partnership

0

 

LASHMA team and HCPAN delegation during the visit

The Healthcare Providers Association of Nigeria (HCPAN), Lagos State Chapter, has called for stronger collaboration with the Lagos State Health Management Agency (LASHMA) to address critical issues affecting healthcare providers and strengthen the implementation of health insurance in Lagos State.

The call was made during a courtesy visit, made by the newly elected executive members of the association to the Permanent Secretary of LASHMA, Dr Emmanuella Zamba, at the agency’s office on Wednesday.

Receiving the delegation led by the HCPAN newly elected Chairman, Mr Abimbola Julius.Adekoya, Dr Zamba expressed the agency’s readiness to work closely with the association

Describing the engagement as a “family meeting,” the Permanent Secretary acknowledged HCPAN as a critical stakeholder in the actualisation of Universal Health Coverage (UHC) in Lagos State. She explained that the meeting was convened to ensure a common understanding between the agency and healthcare providers on the state government’s health insurance implementation agenda.

Speaking on behalf of HCPAN Lagos, Mr Adekoya identified key areas requiring attention to ensure a mutually beneficial relationship between healthcare providers and the state government.

He specifically highlighted the need for a review of providers’ reimbursement rates and tariffs to reflect prevailing economic realities, greater professional inclusiveness in the implementation of the health insurance programme, efficient claims processing and prompt payment mechanisms, as well as simplified enrolment procedures and improved engagement with healthcare providers.

Adekoya emphasised that the success of health insurance depends not only on citizens’ enrolment but also on the ability of healthcare providers to deliver quality services under fair, sustainable and clearly defined operating conditions.

He further stressed that all professional groups affiliated with HCPAN should be recognised and accommodated within the implementation framework, noting that the effective participation of different healthcare professionals is essential to achieving comprehensive and accessible healthcare services.

The immediate past President of HCPAN Nigeria, Dr Jimmy Adeyeye Arigbabuwo, also called for sustained capacity-building programmes to educate healthcare providers and other stakeholders on their respective responsibilities in achieving Universal Health Coverage in Lagos State.

He maintained that continuous stakeholder education would promote better understanding of the health insurance system, improve service delivery and minimise operational challenges.

Similarly, the immediate past Chairman of HCPAN Lagos, Pharmacist Biola Paul-Ozieh, commended Dr Zamba for her efforts in advancing the agency’s activities. She urged both LASHMA and healthcare providers to sustain dialogue, cooperation and collaboration, stressing that the success of ILERA EKO would depend on their collective willingness to identify challenges and work towards practical solutions.

Responding to the issues raised, Dr Zamba appreciated the constructive feedback from the HCPAN delegation and assured the association that the concerns would receive attention.

On providers’ reimbursement and tariff review, she acknowledged the need to examine the existing rates but explained that reimbursement levels were also influenced by the premiums affordable to enrollees.

 She noted that the tariff was due for review after the stipulated two-year period and urged healthcare providers to understand and follow the necessary administrative procedures.

The Permanent Secretary expressed hope that the review process would accommodate a tariff adjustment in 2027.

 

She also assured the delegation that the agency would work on improving claims processing and payment mechanisms, recognising the importance of these processes to the sustainability of healthcare facilities participating in the insurance scheme.

 

In a further demonstration of her commitment to sustained engagement, Dr Zamba expressed her willingness to attend the proposed HCPAN Lagos retreat and participate in the association’s planned regular webinar series. The proposed engagements are expected to provide additional platforms for dialogue, professional education and the resolution of emerging challenges in the health insurance system.

The HCPAN delegation comprised the Chairman Mr Adekoya; Deputy Chairman, Dr Deji Akinlade; General Secretary, Pharmacist Ajalo Abraham; and Publicity Secretary, Mr Jimoh Ayuba.

Members of the LASHMA team included Dr Abiola Idowu, retired permanent secretary and consultant on eegulations; Tosin Awosika, coordinator, regulation; Rotimi Olatunji, head of business development; Dr Nifesimi Akningbe, technical adviser to the permanent secretary; Olawunmi Akinsanmi, Quality Assurance and Enforcement Manager; among others.

 

WHO lists Nigeria among 30 countries bearing highest TB Burden

0

WHO lists Nigeria among 30 countries bearing highest TB Burden

The World Health Organisation (WHO) has identified thirty countries leading with the highest burden of Tuberculosis,with the inclusion of Nigeria, attributing the 88 per cent of the global TB burden in 2025 to them.

In its Global Tuberculosis Report 2026 released on 12 November, the WHO estimated that 10.6 million people developed TB in 2025, while 1.1 million died from the disease

Some of the countries highlighted by the global health agency are India, Indonesia, the Philippines, China, Pakistan, Nigeria, Democratic Republic of Congo, Bandgladesh and others.

Among them, India recorded the highest share at 25 per cent, followed by Indonesia with 10 per cent and the Philippines with 6.8 per cent.

China accounted for 6.5 per cent, Pakistan 6.4 per cent, Nigeria 4.9 per cent, the Democratic Republic of the Congo 3.9 per cent and Bangladesh 3.7 per cent. Together, these eight countries accounted for approximately 67 per cent of people who developed TB worldwide. The remaining 22 countries made up the rest of the 88 per cent.

Despite the high number of cases, the report showed that TB deaths had fallen by 35 per cent since 2015, while treatment had saved an estimated 86 million lives since 2000.

However, the decline in new infections has been slower than expected. The global TB incidence rate fell by 14 per cent between 2015 and 2025, missing the 50 per cent reduction target set under WHO’s End TB Strategy.

WHO Director-General, Dr Tedros Adhanom Ghebreyesus, described the decline in cases and deaths as encouraging, particularly as countries struggle with cuts in international health funding.

He said several governments had increased spending from their own budgets to protect the progress made against the disease.

The report showed that domestic funding for TB programmes rose by 14 per cent to US$5.6 billion between 2024 and 2025, helping to offset a similar decline in international financing.

However, gaps in diagnosis and treatment remain. Of the 10.6 million people estimated to have developed TB in 2025, only 8.4 million were diagnosed, leaving about 2.2 million undiagnosed or unreported.

The use of WHO-recommended rapid diagnostic tests also remained below target, with only 59 per cent of newly diagnosed patients receiving the tests, compared with the 100 per cent target set for 2027.

Drug-resistant TB presents another challenge. An estimated 370,000 people developed rifampicin-resistant TB in 2025, but only 42 per cent received treatment.

WHO also raised concerns about the limited funding available for TB research. Investment stood at US$1.2 billion in 2023, less than one-quarter of the US$5 billion annual target required by 2027.

The organisation called on governments and partners to increase funding, improve access to early diagnosis and treatment, and invest in new vaccines, medicines and diagnostic tools.

It stressed that stronger efforts are needed to sustain the progress already made and accelerate the global response to tuberculosis

 

A patient taking carbamazepine develops reduced anticoagulant effects after starting..

5

PANS QUIZ

1. A patient taking carbamazepine develops reduced anticoagulant effects after starting another medication. Which pharmacokinetic mechanism best explains this interaction?
A. Inhibition of CYP2C9-mediated metabolism
B. Competitive inhibition of renal tubular secretion
C. Inhibition of intestinal P-glycoprotein
D. Induction of hepatic drug-metabolising enzymes

2. Which of the following best explains why methotrexate toxicity can be increased by concomitant administration of trimethoprim?
A. Both drugs inhibit dihydrofolate reductase
B. Trimethoprim accelerates methotrexate glucuronidation
C. Both drugs inhibit xanthine oxidase
D. Methotrexate increases trimethoprim renal filtration

Bloom Public Health, Centenary City partner on Abuja Pharma Park

0

 

Bloom Public Health, Centenary City partner on Abuja Pharma Park
Prof. Chimezie Anyakora

Nigeria’s pharmaceutical manufacturing capacity is set for a potential boost with the development of a Pharmaceutical and Biotechnology Industrial Park, known as Pharmacity, in Abuja through a partnership between Bloom Public Health and Centenary City.

The project, being developed through Bloom Pharmacity Limited, is designed to provide an integrated industrial environment for pharmaceutical manufacturers, biotechnology companies and healthcare supply-chain operators seeking to establish or expand production facilities in Nigeria.

The initiative comes amid growing calls for increased domestic pharmaceutical production as Nigeria seeks to reduce its dependence on imported medicines and strengthen healthcare supply-chain resilience. Africa’s pharmaceutical market was valued at approximately $27.65 billion in 2024 and is projected to reach $36.96 billion by 2033, according to Grand View Research.

Nigeria’s pharmaceutical market, estimated at about $3.34 billion in 2026, is projected to grow annually by 9.5 per cent through 2033, according to Coherent Market Insights.

Despite these growth prospects, Nigeria remains substantially dependent on imported medicines and pharmaceutical inputs. The National Agency for Food and Drug Administration and Control (NAFDAC) has identified the expansion of local manufacturing as an important component of the country’s medicine security strategy.

Against this background, Pharmacity is being developed within Centenary City, Abuja, to attract investment into pharmaceutical and biotechnology manufacturing while providing the infrastructure and technical support required to establish production facilities.

The project will occupy several hectares of master-planned industrial land, with serviced plots of approximately 5,000 square metres allocated to prospective manufacturers. Its proposed infrastructure includes internal road networks, power distribution, water supply, effluent and sewage treatment facilities, and gas reticulation.

Bloom Public Health will serve as the technical partner, providing support in Good Manufacturing Practice (GMP) quality management systems, facility layout planning and regulatory-readiness advisory to help participating manufacturers work towards applicable NAFDAC requirements and relevant international standards, including World Health Organisation prequalification requirements where applicable.

The project partners said the model recognises that establishing pharmaceutical manufacturing facilities requires more than acquiring land and installing production equipment, as facility design, production processes, quality assurance, regulatory compliance, utilities, workforce capacity and supply-chain reliability are equally important. By bringing manufacturing facilities and supporting services together within a coordinated industrial zone, Pharmacity aims to improve infrastructure efficiency, reduce duplication of investment and address some of the operational challenges associated with establishing pharmaceutical production facilities.

Speaking on the initiative, Chief Executive Officer of Bloom Public Health, Prof. Chimezie Anyakora, said the project was designed to strengthen Nigeria’s healthcare security through sustainable local manufacturing.

“Nigeria’s healthcare security depends on building sustainable, quality-assured local manufacturing capacity. Pharmacity is designed to move beyond basic industrial real estate by giving pharmaceutical and biotechnology manufacturers an ecosystem where physical infrastructure is directly supported by GMP quality systems and regulatory readiness from the outset,” he said.

The proposed industrial park will incorporate facilities and services to support pharmaceutical manufacturing, including cold-chain and warehousing logistics hubs, quality-control laboratories, regulatory liaison offices and commercial banking services. Its location within Centenary City, close to the Nnamdi Azikiwe International Airport, is expected to provide access to air cargo services and distribution networks across Nigeria and the wider West African market. The project’s position within Centenary City’s Free Zone framework is also expected to offer eligible businesses access to applicable tax, customs and other investment incentives, subject to the necessary approvals and regulatory conditions.

Pharmacity is currently in its primary and secondary infrastructure rollout phase, with the onboarding of initial facilities targeted for the first quarter of 2027. The development is expected to create opportunities for pharmaceutical manufacturers, biotechnology companies, institutional investors, infrastructure providers and specialised healthcare logistics operators. Its success will ultimately depend on its ability to attract credible manufacturers, mobilise investment and support quality-assured production facilities capable of meeting local and international standards.

Bloom Pharmacity Limited has invited pharmaceutical manufacturers, biotechnology companies, infrastructure investors and healthcare logistics operators to engage with its project team. Interested parties can request the project prospectus, obtain information on plot specifications or arrange site visits through the project secretariat.

 

World Bank’s IMPACT Project: Pate seeks sustained gains

0
World Bank’s IMPACT Project: Pate seeks sustained gains
Prof. Muhammad Ali Pate

The Coordinating Minister of Health and Social Welfare, Prof. Muhammad Pate, has urged sustained commitment to health sector reforms to consolidate gains recorded under the World Bank-funded IMPACT Project.

Pate made the call at the end-of-project dissemination of the Immunisation Plus and Malaria Progress by Accelerating Coverage and Transforming Services (IMPACT) Project in Abuja.

The event was part of activities marking the close of the 2026 Health Sector Joint Annual Review (JAR), which began on Tuesday.
Pate said Nigeria’s health sector reforms had evolved over more than two decades, shifting from investments in infrastructure, equipment and procurement to approaches focused on measurable health outcomes.

“Nigeria’s health reform journey has been a long one. There’s an evolution that has been going on for 22 years in Nigeria’s healthcare system,” he said.

He said the shift towards results-based financing reflected the need to prioritise measurable outcomes rather than activities.
“The paradigm shift is that you cannot reward effort. You need to reward result,” Pate said.

He said the IMPACT Project, approved in 2020 with 650 million dollars in financing, represented the first phase of a multi-phase programme.
According to him, the project helped facilitate the transition from investment lending to a results-based system anchored on the Basic Health Care Provision Fund (BHCPF).

“The challenge for us is then how to sustain it, because reform is a continuous process,” he said.

Pate said subsequent phases would build on the project’s achievements through the Health Sector Renewal Investment Initiative, the Sector-Wide Approach and the HOPE programme.

The World Bank Country Director, Matthew Verghis, said the project demonstrated the value of sustained investment in primary healthcare and collaboration across different levels of government.

Verghis said the project increased health facility quality-of-care scores from 39.3 per cent to 50.2 per cent and upgraded more than 2,600 Primary Health Care (PHC) facilities.

He said more than 10 million insecticide-treated nets were procured and distributed, while over 20 million dollars was transferred directly to PHC facilities.

The project also financed about 170 million dollars in routine vaccine procurement over four years, helping Nigeria meet its domestic co-financing obligations and access vaccine financing, he said.

Verghis added that more than 15,000 health workers were engaged to address staffing gaps, while over 6,000 PHC facilities received laptops.
He said the gains would be sustained through the Health Sector Renewal Investment Initiative and the HOPE programmes.

“Project closure is not the end of this journey,” Verghis said, urging stakeholders to integrate the project’s lessons and investments into stronger national health systems.

The National Coordinator, National Malaria Elimination Programme (NMEP), Dr Nnenna Ogbulafor, said malaria prevalence declined from 27 per cent at the beginning of the project to 15.2 per cent.

She said the project also supported Nigeria’s 2025 Malaria Indicator Survey with minimal assistance from other partners.

Ogbulafor said it facilitated the development of the National Malaria Strategic Plan 2026–2030 and supported the country’s largest larval source management intervention.

She added that the project supported locally produced next-generation insecticide-treated nets and strengthened malaria diagnosis, treatment and commodity distribution.

The Executive Director and Chief Executive Officer of the National Primary Health Care Development Agency (NPHCDA), Dr Muyi Aina, said the project contributed to improved immunisation coverage and primary healthcare delivery.

Aina said 16.6 million children were fully immunised, exceeding the project target of 9.3 million.

He said the proportion of fully immunised children aged 12 to 23 months rose from 31 per cent to 39.7 per cent, surpassing the 36 per cent target.

According to him, malaria prevalence declined from 22 per cent in 2021 to 15 per cent in 2025, while under-five mortality fell from 102 to 90 deaths per 1,000 live births.

He said more than 2,500 PHC facilities were upgraded to Level Two functionality across 30 states and the Federal Capital Territory (FCT).
Other interventions included financing 200 million vaccine doses between 2023 and 2025, providing 3,144 solar direct-drive refrigerators and distributing 4.68 million long-lasting insecticidal nets.

Aina said 5.8 million pregnant women also received at least three doses of intermittent preventive treatment for malaria.

He urged state and local governments to take ownership of the facilities, equipment and other assets provided under the project.

“The IMPACT Project closes on Dec. 31, but a health centre does not,” he said.

The National Programme Manager of the IMPACT Project, Dr Amina Mohammed, said implementation began in February 2021, expanding from 18 states to 30 states and the FCT.

Mohammed said the project had three main components: Immunisation Plus, Knowledge for Change and Malaria, while a fourth emergency response component was not activated.

She said under-five mortality declined from 132 to 90 deaths per 1,000 live births, while the proportion of febrile children receiving artemisinin-based combination therapy increased from 8.1 per cent to 47.2 per cent.

She added that the project supported the training of 79,000 healthcare workers and established a vaccine storage hub in Lagos.

The event also featured awards to individuals and teams recognised for their contributions to the project’s implementation.

The News Agency of Nigeria (NAN) reports that the IMPACT Project was designed to improve immunisation coverage, expand access to malaria interventions and reduce under-five mortality through investments in PHC, vaccines, commodities, infrastructure and health systems.

It was implemented through national agencies and state institutions with support from the World Bank. (NAN)

Prioritise medicine security, establish implementation group, NAIP chairman tells PSN leaders

0

 

Prioritise medicine security, establish implementation group, NAIP chairman tells PSN leaders
Bankole Ezebuilo

Pharm. Sir Bankole Aminu Ezebuilo is the national chairman of the Association of Industrial Pharmacists of Nigeria (NAIP). In this interview with Ranmilowo Ojalumo, he urges the Pharmaceutical Society of Nigeria (PSN) to place medicine security at the centre of its 99th Annual National Conference and establish a group to drive the implementation of conference resolutions. He also discusses the challenges facing Nigeria’s pharmaceutical industry, the fight against substandard and falsified medicines, and initiatives to strengthen local manufacturing. Excerpts:

What is your general assessment of the current state of the pharmaceutical industry?

Nigeria’s pharmaceutical industry has considerable potential, but this has yet to translate into a sufficiently resilient medicine supply system. The country has experienced pharmacists, established manufacturers, research institutions and a large population whose medicine needs should provide a strong basis for investment. Yet access to medicines remains vulnerable to imports, dependence on imported manufacturing inputs and disruptions beyond our borders.

The World Health Organisation’s 2025 Nigeria health systems profile identifies limited domestic production and dependence on imports as important weaknesses. This points to a structural gap rather than providing a real-time assessment of production levels. The central concern is that our capacity to meet essential medicine needs locally remains inadequate.

For an industrial pharmacist, the challenge goes beyond producing a tablet or capsule. A dependable pharmaceutical industry requires validated processes, functional laboratories, trained personnel, reliable utilities, appropriate storage facilities and sufficient working capital. When manufacturers face high financing costs and unpredictable input prices, upgrading facilities, maintaining stocks and offering competitive prices become more difficult. Patients ultimately bear the consequences through reduced affordability and availability.

The government has recognised the need for change through the Presidential Initiative for Unlocking the Healthcare Value Chain and fiscal measures designed to support domestic production. In March 2025, the Nigeria Customs Service published implementation guidelines covering eligible pharmaceutical manufacturing inputs. These are useful policy measures, but their effectiveness must be assessed by how readily manufacturers can access the benefits and the extent to which they improve medicine supply.

We should progressively strengthen domestic capacity, prioritising essential medicines and products that Nigeria can manufacture competitively while meeting quality standards. Imports will continue to play a role. The objective should be a balanced pharmaceutical supply system that can withstand disruptions and provide Nigerians with dependable access to the medicines they need.

As pharmacists gather in November for another PSN conference, what paramount issue would you want the society to pay attention to?

I would place medicine security at the centre of the conference. By medicine security, I mean the ability to provide safe, effective, quality-assured and affordable medicines consistently, including during economic difficulties, emergencies and international supply disruptions.

This is a professional issue with direct consequences for households. A prescription is of limited value if the medicine is unavailable, unaffordable or of uncertain quality. We should therefore measure our professional contribution by whether patients can complete their treatment safely and reliably.

The PSN can bring together the different parts of the pharmaceutical system. Industrial pharmacists understand manufacturing and product quality, while community and hospital pharmacists encounter challenges relating to medicine availability, affordability and treatment interruptions. Academics and researchers can contribute to product development, evidence generation and professional training. Bringing these perspectives together would make the conference’s recommendations more relevant and practical.

I would like the conference to examine which essential medicines experience supply shortages, what prevents reliable local production, where distribution systems break down and how procurement can support dependable supply. These questions should be addressed using data rather than impressions alone.

Workforce competence must also feature in the discussions. Nigeria needs pharmacists who can work effectively in formulation development, quality assurance, regulatory affairs, manufacturing and supply chain management. We should consider how pharmacy education, practical placements and continuing professional development can be aligned with these needs.

The conference should produce a shared understanding of the challenges and identify a manageable number of priorities that the profession can pursue collectively. Medicine security is broad enough to unite pharmacists across practice areas, but it must be translated into specific actions to deliver meaningful results.

What major issue should the conference discuss and back up with immediate action?

The immediate priority should be to remove the practical barriers to the reliable production and distribution of quality-assured essential medicines. Another broad resolution will have limited value unless someone is responsible for implementing it.

I would recommend that the PSN convene a focused implementation group involving NAIP, pharmaceutical manufacturers, relevant regulators, procurement institutions, researchers and financing partners. This is a proposal for the conference to consider, not an announcement that such a programme has already been established.

Within the first 30 days, the group should agree on a manageable set of priorities and gather evidence from manufacturers and medicine users. Within 60 days, it should identify the main constraints, the institutions responsible for addressing them and the decisions required. Within 90 days, it should present an action plan with designated leads, realistic timelines and a mechanism for reporting progress.

The agenda should cover access to appropriate financing, the implementation of manufacturing incentives, essential infrastructure and predictable demand. Long-term investment in manufacturing facilities and short-term working capital require different financing arrangements. A manufacturer may be able to purchase equipment but still struggle to finance raw materials, testing and distribution while awaiting payment.

Workforce development must form part of this immediate action. NAIP is partnering with UNICEF to train young graduates in pharmaceutical manufacturing, with participants receiving payment during their training. This approach helps bridge the gap between academic preparation and industrial practice while providing financial support as graduates develop their skills. It is a practical example of investing in the people needed to sustain local production.

The conference should consider how to support and expand such opportunities through partnerships with industry. Training should be assessed by the competencies participants acquire and their progression into productive roles. Stronger pharmaceutical factories need personnel who can operate processes correctly, maintain accurate records and uphold quality standards. Investment in equipment and workforce development should therefore proceed together.

Alongside manufacturing finance, and workforce development, we must address access to sustainable markets. Manufacturers need confidence that their quality products will reach dependable buyers. NAIP’s collaboration with the African Resource Centre for Excellence in Supply Chain Management (ARC-ESM) and state Drug Management Agencies on pooled procurement is also relevant to this discussion.

Consolidating purchasing needs can generate greater, more predictable demand and strengthen buyers’ negotiating positions. For qualified local manufacturers, greater visibility of expected demand can support production planning, investment decisions and more efficient use of capacity. The conference should examine how Nigerian manufacturers can participate effectively and what quality, supply and contracting requirements they must meet.

Pooled procurement must be supported by transparent supplier selection, rigorous quality assurance, realistic delivery schedules and timely payments. Consolidating orders alone will not solve supply problems if manufacturers cannot finance production or purchasing institutions delay settlement. Our objective should be a procurement system that promotes reliable supply and better value for patients while giving capable manufacturers a fair opportunity to compete.

Progress should be measured against a few meaningful indicators, including supply lead times, stock availability, quality compliance and payment performance. The PSN should report what has changed, what remains unresolved and what requires government intervention. This would ensure that conference resolutions remain relevant long after the closing ceremony.

What is your key message to the leadership of the PSN and the Nigerian government?

To the PSN leadership, my message is that our professional credibility should underpin sustained, evidence-based advocacy. We need a clear agenda that connects the concerns of pharmacists with patients’ needs and the country’s development priorities.

The PSN should coordinate its technical groups around common goals while drawing on their respective areas of expertise. It should maintain dialogue with the government throughout the year, document the evidence supporting its recommendations and report progress on major commitments. This would make our advocacy easier to evaluate and harder to dismiss.

To the government, my message is that pharmaceutical investment requires policy continuity and effective implementation. Manufacturers make decisions that span several years. They need confidence that approved incentives will be accessible, administrative requirements will be clear and policy changes will be communicated predictably.

The government’s published manufacturing incentives provide a useful foundation. The next step is to ensure that eligible companies can access them without avoidable delays and that the benefits translate into increased production and improved patient access. Implementation should be monitored transparently, while any extension or modification of time-limited measures should be communicated early enough for businesses to plan.

Financing arrangements must also reflect the needs of the sector. Manufacturing facilities, quality systems and research cannot always be funded on terms designed for rapid commercial turnover. The government and financial institutions should develop arrangements that recognise investment lead times while maintaining sound commercial discipline.

Public support must come with accountability. Beneficiary companies should demonstrate compliance with quality standards, responsible use of support and credible improvements in medicine supply. Industry, in turn, must provide transparent evidence of what it can deliver.

Ultimately, the test is straightforward: are Nigerians obtaining quality medicines more reliably and at prices they can afford? That question should guide the relationship between the government, the pharmaceutical profession and industry.

What is your take on fake medicines in Nigeria, and what is NAIP doing about the problem?

Substandard and falsified medicines threaten lives and undermine public confidence in the healthcare system. They also disadvantage legitimate businesses that invest in proper manufacturing, testing and regulatory compliance. However, I would avoid claiming that their prevalence is increasing without comparable surveillance data. An increase in detections may reflect more wrongdoing, improved surveillance or a combination of both.

We need to distinguish between the different categories of poor-quality medicines. Falsified medicines deliberately misrepresent their identity, composition or source. Substandard medicines are authorised products that fail to meet the required quality standards or specifications. Quality failures may result from manufacturing deficiencies or deterioration during storage and transportation. Although these categories require different investigations, both demand prompt action to protect patients.

Public alerts issued by the National Agency for Food and Drug Administration and Control (NAFDAC) demonstrate the need for vigilance and purchasing through authorised suppliers. The appearance of a product or the presence of a printed registration number should not, on its own, be regarded as conclusive proof of authenticity.

NAIP represents the pharmaceutical industry, including manufacturers, importers, Nigerian companies representing overseas firms and pharmacists involved in consultancy. Our responsibility is to promote the professional competence and ethical conduct required to protect product quality throughout the medicine lifecycle. This includes sound formulation, validated manufacturing processes, accurate documentation, appropriate testing, controlled storage and effective responses to complaints or suspected defects.

The capacity-building partnerships we are pursuing provide a platform for strengthening these capabilities. Quality management systems, good manufacturing practice and professional accountability are essential priorities. We must encourage our members to report suspected falsified products, cooperate with investigations and support prompt recalls where necessary.

We must also be clear about institutional responsibilities. NAIP is a professional association and does not replace NAFDAC or other statutory bodies in enforcement. Our contribution is to strengthen professional practice, support informed policymaking and encourage cooperation with regulators. I would not claim that NAIP has reduced the prevalence of falsified medicines without evidence to substantiate such a claim.

How can Nigeria, as a nation, solve the problem?

Nigeria needs a system that makes unsafe medicines harder to introduce into the market, easier to detect and more costly to trade in. Enforcement is essential, but it must be supported by reliable supplies, accountable distribution systems and informed purchasing.

First, medicines should move through authorised and traceable channels. Suppliers must be identifiable, transactions documented and storage conditions appropriate. When a defective batch is discovered, there should be sufficient information to establish where it has been distributed and retrieve it promptly.

Second, pharmaceutical traceability should be implemented practically and consistently. NAFDAC has published the Pharmaceutical Products Traceability Regulations, 2024. Traceability can support authentication, investigations and targeted recalls, but it depends on reliable data and participation across the supply chain. A code on a medicine pack cannot replace laboratory testing, inspection or sound procurement practices.

Third, regulatory agencies need adequate resources for risk-based inspections, laboratory analysis, market surveillance and timely public communication. NAFDAC, the Pharmacy Council of Nigeria, the Nigeria Customs Service and relevant security agencies should cooperate within their respective mandates. Sharing intelligence can help identify repeat offenders and the distribution routes used to circulate unsafe medicines.

Fourth, deliberate falsification requires effective investigation and prosecution. Enforcement should target those financing and organising the trade while safeguarding the integrity of evidence and due process. Manufacturers must also investigate genuine quality failures and take corrective action rather than dismissing every complaint as counterfeiting.

Fifth, we must address the conditions that expose patients to unsafe sources of medicines. Affordable and dependable supplies of quality-assured products are part of the solution. Public education should encourage people to purchase medicines from licensed outlets and explain how to report concerns, while recognising that patients cannot reliably determine pharmaceutical quality by appearance alone.

Success should be measured through surveillance evidence, faster detection and recalls, improved regulatory compliance and more dependable legitimate supplies. The number of raids alone cannot establish whether patients are becoming safer.

You have embarked on activities since becoming NAIP chairman. Kindly take us through your initiatives and outcomes.

Since assuming office in July 2025, my focus has been on strengthening NAIP’s contribution through industry dialogue, professional development and partnerships capable of delivering practical benefits. These remain ongoing responsibilities, and I believe it is important to distinguish between activities undertaken and outcomes that still require measurement.

Our 2026 Economic Outlook and CEOs Forum in Lagos centred on the theme Reimagining Nigeria’s Health Security. It provided an opportunity to bring industry concerns into a broader discussion on investment, policy and dependable medicine supply. Engagement with industry leaders and regulatory stakeholders is valuable because many of the constraints facing pharmaceutical companies require decisions beyond the control of individual businesses.

Our training conference in Ilorin, themed Collaboration and Innovation, combined professional engagement with community service. The outreach included a health walk, free medical services at the Emir’s Palace, the opening of a health centre and medicine donations valued at approximately N5 million. These activities connected professional discussions with practical service to the community.

During my first year as national chairman, we have focused on strengthening NAIP’s support for members through strategic partnerships, practical capacity-building initiatives and direct engagement with pharmaceutical companies.

We have signed a memorandum of understanding (MoU) with the African Resource Centre for Excellence in Supply Chain Management (ARC-ESM) to provide supply chain management training aimed at strengthening the skills required to manage pharmaceutical supply chains effectively.

Our MoU with the Indian High Commission focuses on addressing the technical and equipment-related challenges facing NAIP members. The partnership is intended to connect companies with relevant expertise and support.

What does NAIP anticipate in the near future for the advancement of industrial pharmacy in Nigeria?

Our focus is on strengthening technical competence, building practical partnerships and creating better opportunities for industrial pharmacists at different stages of their careers.

Babalola tasks PSN president on accountability, medicine affordability, pharmacists’ welfare

0

 

Babalola tasks PSN president on accountability, medicine affordability, pharmacists’ welfare
Prof. Chinedum Peace Babalola

Former Vice-Chancellor of Chrisland University, Professor Chinedum Peace Babalola, has outlined a set of priorities for the President of the Pharmaceutical Society of Nigeria (PSN), Pharm. Tanko Ayuba, to address during his remaining year in office. In an exclusive chat with Pharmanews, Babalola said the priorities include accountability, medicine affordability, pharmacists’ welfare and stronger institutional reforms.

While acknowledging the reported progress made under Ayuba’s administration in professional advocacy, regulatory matters involving pharmaceutical technologists and veterinary medicines, and internship placement, Babalola called for a clear assessment of the administration’s achievements during its first two years. She also urged the PSN president to develop a well-defined action plan for his final year, particularly as the Society approaches its centenary.

The first female professor of pharmacy at the University of Ibadan said the president should prioritise medicine affordability by promoting quality-assured local production and strengthening collaboration among the PSN, the Nigeria Association of Industrial Pharmacists (NAIP), academia, manufacturers, the National Agency for Food and Drug Administration and Control (NAFDAC), and government. Such collaboration, she said, should produce practical solutions to high production costs, dependence on imported pharmaceutical inputs, limited bioequivalence testing capacity and inadequate access to affordable, quality-assured medicines.

Babalola also called on the PSN president to improve pharmacists’ welfare, particularly that of those in academia. She maintained that the expansion of pharmacy schools must be accompanied by adequate facilities, sufficient qualified personnel and better working conditions.

“We should not measure progress only by the number of schools established. We must strengthen existing institutions, improve staff welfare, retain our best academic talent and ensure that expansion is matched by capacity,” she said.

She further urged the Pharmacy Council of Nigeria (PCN), as the regulator of pharmacy education and practice, to work with universities and other relevant authorities to assess academic manpower requirements, vacancies, specialist disciplines, projected retirements and future training needs.

As the PSN approaches its centenary, Babalola said Ayuba should aim to leave behind a stronger institution characterised by greater unity, improved member welfare, better prospects for academic pharmacists, stronger regulatory collaboration and demonstrable progress in medicine security.

“My assessment, therefore, is that the administration has kept important professional and regulatory matters on the agenda. The opportunity in the remaining period is to move from advocacy to implementation, from reported achievements to verifiable outcomes, and from individual initiatives to lasting institutional reforms. That would be a meaningful contribution to the Society’s next century,” she said.

Speaking on the forthcoming 99th Annual National Conference of the PSN, tagged Ijele 2026, Babalola described the theme, “One Health, One Pharmacy: Bridging Knowledge, Practice and Policy for National Impact”, as exceptionally apt and timely. She said it challenges pharmacists to recognise that human health cannot be considered in isolation from animal health, the environment, food safety and the wider systems that influence population health.

To prevent conference deliberations from ending with the presentation of a communiqué, she proposed establishing a Conference Resolutions Implementation Committee to select one or two priority resolutions, assign responsibilities, set timelines, identify resources and report progress to members.

Babalola further discusses her expectations for the conference, practical strategies for reducing medicine costs, the need to strengthen local pharmaceutical production and the priorities she believes the PSN should pursue as it prepares to enter its second century.

Below is the full interview:

The PSN National Conference is around the corner, with the theme, “One Health, One Pharmacy: Bridging Knowledge, Practice and Policy for National Impact.” In your view, how apt is this theme at this time, and what does it mean for the pharmacy profession and the wider healthcare system?

Nigeria faces several interconnected health challenges, including antimicrobial resistance, infectious diseases, environmental contamination, the circulation of substandard and falsified medicines, and inadequate access to affordable, quality-assured medicines. These challenges cannot be resolved by one profession or agency acting alone.

Consider antimicrobial resistance. The inappropriate use of antibiotics in humans and animals, poor infection prevention and the release of pharmaceutical residues into the environment can all contribute to a problem that threatens the effectiveness of existing treatments. Pharmacists must work with physicians, veterinarians, microbiologists, environmental scientists and public health authorities to promote antimicrobial stewardship, strengthen surveillance and protect the effectiveness of our medicines.

The theme is also relevant to medicine quality and national pharmaceutical security. We must look beyond whether a medicine is available and ask whether it is authentic, safe, effective, properly stored and affordable. Pharmacists contribute throughout the medicine lifecycle, from research and formulation to manufacturing, quality assurance, distribution, dispensing and post-market surveillance.

However, the phrase “bridging knowledge, practice and policy” is particularly important to me. Nigeria has capable researchers, universities, pharmaceutical manufacturers and regulatory institutions. We have generated considerable scientific knowledge, but we must do more to translate that knowledge into products, professional practice, policy decisions and measurable improvements in public health.

We must invest in relevant research that addresses Nigerian health needs, including medicine quality, antimicrobial resistance, pharmacokinetics, drug safety and pharmaceutical innovation. We must also ensure that research findings influence the work of pharmacists and other healthcare professionals in hospitals, community pharmacies, laboratories, industry and public health programmes. Equally important is the translation of scientific evidence into appropriate regulations, funding decisions, procurement policies, professional standards and sustainable health programmes.

I therefore believe the PSN should not allow this theme to remain a conference slogan. I would like to see a practical One Health action framework with clearly identified partners, timelines and indicators of progress.

Ultimately, the success of One Health, One Pharmacy will not be measured by the eloquence of our presentations, but by whether our collaboration protects lives, improves access to quality medicines, strengthens pharmaceutical security and contributes to a healthier Nigeria.

 

The rising cost of medicines remains a major concern for patients. What practical steps can the PSN, in collaboration with NAIP and other stakeholders, take to reduce the cost of local pharmaceutical production and ultimately make medicines more affordable and accessible to Nigerians?

The rising cost of medicines is a serious public health and socioeconomic concern. When medicines become unaffordable, patients may delay treatment, skip doses, buy incomplete courses or resort to products of uncertain quality. The consequences can include worsening illness, treatment failure and greater financial pressure on families.

In my view, we must go beyond asking manufacturers to reduce prices. We need to address the structural factors that make pharmaceutical production expensive in Nigeria, including dependence on imported active pharmaceutical ingredients (APIs) and excipients, foreign exchange fluctuations, energy and logistics costs, expensive financing, and the cost of meeting quality and regulatory requirements.

My central proposal is a structured partnership among industry, academia, regulators and government. The PSN and NAIP should jointly champion a mechanism that connects our research capacity to the practical needs of pharmaceutical manufacturers and the health system.

One opportunity is to develop pharmaceutical raw materials from locally available resources. Nigeria has agricultural, chemical and petrochemical resources that could support the production of selected pharmaceutical inputs. Cassava can provide starch for pharmaceutical excipients and, through appropriate processing, feedstocks for industrial ethanol production. Maize and other agricultural materials may provide starches, cellulose, gums, oils and mucilages with pharmaceutical applications. Petrochemical industries may also supply selected solvents and chemical intermediates.

Nigerian researchers have already investigated some of these possibilities. We must now establish a stronger pathway from laboratory findings to industrial-scale production. This will require product characterisation, purification, standardisation, quality assurance, investment and dependable markets. Locally sourced materials must meet pharmaceutical standards; their availability alone does not make them suitable for medicinal use.

Another priority is to translate promising research into products. Our universities and research institutes have expertise in formulation development, medicinal chemistry, pharmacokinetics, drug delivery and medicinal plants. Yet promising research can remain in academic journals without reaching manufacturers or patients.

I propose a national industry-academia-regulatory collaboration platform involving the PSN, NAIP, universities, the National Institute for Pharmaceutical Research and Development (NIPRD), NAFDAC, pharmaceutical manufacturers, investors and relevant government agencies. The platform should identify promising research, match researchers with industrial partners, facilitate access to pilot plants and analytical laboratories, clarify intellectual property and licensing arrangements, and establish early agreement on the regulatory evidence required for product development.

We should also invest in our medicinal biodiversity. Nigeria has a rich heritage of medicinal plants and locally available food plants that researchers have investigated for possible antimicrobial, antimalarial, anti-inflammatory, metabolic and other therapeutic effects. This presents opportunities to develop scientifically validated medicines and nutraceuticals.

Drug repurposing is another area worth exploring. Some existing medicines may have potential for new indications, including selected cancers and other conditions associated with substantial treatment costs. Repurposing can sometimes shorten parts of the development process because information about an existing medicine is already available. However, this does not automatically establish its safety or effectiveness for a new indication. Appropriate studies, ethical oversight and regulatory approval remain essential.

We must also address the cost of bioavailability and bioequivalence (BA/BE) studies. These studies can be expensive for local manufacturers seeking to demonstrate that eligible generic medicines perform comparably to reference products. I would encourage a public-private partnership to establish or strengthen competent contract research organisations and shared BA/BE facilities. Government, industry, academia and development partners could share investment, expertise and infrastructure, while NAFDAC provides appropriate regulatory oversight. Reducing costs must never come at the expense of scientific integrity.

Finally, we must translate policy incentives into measurable benefits for patients. The Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) and the Federal Government’s policy measures to promote local production provide an important foundation. The next step is effective implementation, supported by financing, technology transfer, infrastructure, predictable procurement and measures to strengthen quality-assured domestic production.

Government incentives should deliver public value. Where public funding or procurement commitments support manufacturers, there should be transparent expectations regarding product quality, reliable supply and price competitiveness.

As the PSN prepares for its 99th Annual National Conference, what are your expectations regarding the organisation of the conference, delegates’ welfare, the quality of speakers and presentations, professional networking and the overall experience?

My expectations for the 99th Annual National Conference of the Pharmaceutical Society of Nigeria, Ijele 2026, are high. As the Society approaches its centenary, this conference should demonstrate not only the strength of our professional community but also our capacity for excellence, innovation and effective organisation.

Delegate safety and welfare must be priorities. Transportation should be convenient, information should be communicated clearly, and accommodation, hospitality and programme coordination should meet reasonable expectations. There should also be opportunities for entertainment, cultural engagement and relaxation. We want delegates to enjoy Awka, appreciate Anambra State and return home with a lasting, positive impression of the PSN.

Regarding the quality of speakers and presentations, I expect distinguished resource persons who can offer evidence-based insights, fresh perspectives and practical solutions to the challenges facing pharmacy and healthcare delivery in Nigeria. The conference should also provide meaningful opportunities for professional networking, mentorship for younger pharmacists, and stronger partnerships among academia, industry, regulators, government and development partners.

I would particularly welcome discussions that move beyond identifying problems to proposing workable solutions in areas such as pharmacists’ welfare, academic workforce development, medicine affordability, local pharmaceutical manufacturing, medicine quality, public health and the implementation of pharmacy education reforms.

However, there is one issue I consider especially important: what happens after the conference?

We often organise conferences with excellent speakers, stimulating discussions and well-written communiqués. Yet implementation can remain a challenge. We must not allow our resolutions to become recurring declarations that are revisited at successive conferences without sufficient progress.

I therefore recommend that the PSN establish a Conference Resolutions Implementation Committee with a clear mandate to select one or two priority resolutions, assign responsibilities, establish timelines, identify resources and report progress to members.

The priorities could include improving pharmacists’ welfare and conditions of service, particularly by addressing the remuneration and retention challenges facing academic pharmacists. Another could be strengthening access to quality-assured and affordable medicines through collaboration among the PSN, NAIP, academia, industry, NAFDAC, the PCN and government.

The Society does not have to solve every challenge at once. However, if each conference identifies a small number of achievable priorities and follows them through to completion, we will gradually build a culture of accountability and measurable progress.

As we approach 100 years of the PSN, we should be proud of the foundations laid by successive generations of pharmacists and leaders. We should also be bold enough to ask how we can improve our institutions, strengthen our influence on national policy and deliver greater value to our members and the public.

I want Ijele 2026 to be remembered for excellent organisation, warm hospitality, outstanding presentations, meaningful professional connections and, above all, tangible outcomes.

Beyond temperature, humidity control vital to medicine quality – Sharma

0

 

Anup Sharma

 

In pharmaceutical manufacturing, product quality depends not only on the ingredients used but also on the environment in which medicines are produced. While temperature control often receives considerable attention, humidity and moisture management are equally important for ensuring product stability, manufacturing consistency and operational efficiency. In this interview with Samuel Dike, Anup Sharma, regional head for West Africa at Bry-Air Nigeria Limited, discusses the importance of humidity control, the environmental challenges facing Nigerian pharmaceutical manufacturers, and how modern dehumidification and air-treatment technologies can improve product quality, energy efficiency and manufacturing performance. Excerpts.

Why is humidity as important as temperature in pharmaceutical manufacturing?

Temperature and humidity are equally important in maintaining a controlled pharmaceutical manufacturing environment. While temperature influences reaction rates, product stability and processing conditions, humidity directly affects the moisture content of raw materials, powders, granules, tablets and capsules. Many pharmaceutical ingredients absorb moisture from the surrounding air, potentially becoming sticky, forming lumps and affecting accurate dosing and tablet compression.

Conversely, excessively low humidity can generate static electricity, creating difficulties in powder handling and filling operations. Humidity control is therefore not merely an HVAC requirement; it is a critical process parameter that influences product quality, manufacturing consistency and operational efficiency.

What are the consequences of inadequate humidity control?

Poor moisture control can affect pharmaceutical production at every stage, from raw material storage to final packaging. Moisture-sensitive ingredients may deteriorate, while powders can form lumps, obstruct equipment and flow inconsistently. Variations in moisture content can also affect tablet compression, hardness, disintegration, coating uniformity and filling operations.

During storage and packaging, moisture absorption may compromise product stability and shelf life. These problems can lead to rejected batches, production downtime, rework and additional quality investigations. Manufacturers must therefore establish humidity requirements based on the specific product, manufacturing process and applicable Good Manufacturing Practice (GMP) requirements.

What are the limitations of conventional HVAC systems when precise humidity control is required?

Conventional heating, ventilation and air conditioning (HVAC) systems are designed primarily to regulate temperature, provide ventilation and maintain general indoor environmental conditions. Although they can control humidity within certain limits, maintaining very low and stable humidity levels can be challenging, particularly in tropical climates. Cooling-based dehumidification may require substantial cooling followed by reheating, thereby increasing energy consumption.

Desiccant dehumidification offers an alternative by removing water vapour through adsorption, making it suitable for applications requiring low dew points or precise humidity control. In many pharmaceutical facilities, integrating a properly designed desiccant system with existing HVAC infrastructure can provide a more effective solution than replacing the entire system.

How can modern dehumidification technologies improve energy efficiency?

Modern dehumidification systems can be integrated with cooling coils, heat recovery systems, variable-speed drives and intelligent controls. Depending on the application, these technologies can reduce unnecessary cooling and reheating, reuse suitable waste heat for desiccant regeneration, and improve the management of ventilation and moisture loads.

However, energy savings depend on factors such as climate, required humidity levels, process moisture loads, equipment selection and operating strategy. Manufacturers should assess the total energy consumption of a proposed system rather than focus solely on equipment power ratings. The objective is to maintain the environmental conditions required for product quality while achieving the lowest practical total energy consumption.

What industry challenges have driven Bry-Air and DRI to develop these technologies?

The growing need for precise process control, product protection, energy efficiency and reliable manufacturing has driven the development of advanced dehumidification and air-treatment technologies. Pharmaceutical manufacturers must protect moisture-sensitive ingredients and maintain consistent environmental conditions during powder processing, filling, coating and packaging. Other industries, including food, electronics, chemicals and lithium-ion battery manufacturing, also require specialised environmental conditions.

Bry-Air addresses these needs through technologies covering dehumidification, air purification, heat recovery, cooling and other environmental-control solutions. Since no single HVAC configuration can meet the requirements of every industry, each application demands a clear understanding of the product, manufacturing process, moisture load and required environmental conditions.

What specific problems are Bry-Air’s pharmaceutical solutions designed to address?

Bry-Air’s pharmaceutical solutions address moisture-related challenges across different stages of manufacturing, including cleanrooms, powder milling, tablet compression and coating, capsule production, dry injection and vial filling, as well as the storage of raw materials and finished products. Excess moisture can make powders difficult to handle, disrupt filling operations and affect the consistency of pharmaceutical products.

Humidity management is also important during packaging and storage, particularly for moisture-sensitive medicines and hygroscopic products. The objective is to maintain the environmental conditions required for each process while supporting product consistency and operational reliability. The appropriate solution depends on the specific requirements of the manufacturing application.

 

What are the major environmental-control challenges in Nigeria and other tropical markets?

One of the biggest challenges in Nigeria is the combination of high outdoor humidity, elevated temperatures and the substantial moisture introduced into manufacturing facilities through fresh air. A production room may reach its target temperature while its relative humidity remains above the required limit, particularly during humid weather.

Other challenges include poor insulation, air leakage, inadequately sealed rooms, insufficient preventive maintenance and HVAC systems that are not designed to meet specific production requirements. Manufacturers must consider the building structure, production process, airflow, filtration, equipment, controls and maintenance practices. Environmental control should be approached as an integrated engineering solution rather than simply an equipment purchase.

How can manufacturers balance sophisticated environmental control with energy and cost efficiency?

Manufacturers should design environmental-control systems around actual production requirements rather than over-engineer an entire facility. This begins with establishing the temperature and humidity limits required for each production area, calculating the moisture load and selecting suitable technology. Separate environmental-control zones, energy recovery, calibrated sensors and automated controls can also help improve efficiency.

It is equally important to consider the total cost of ownership, including electricity, maintenance, spare parts, production interruptions, product rejection and equipment lifespan. A higher initial investment may offer better long-term value if it improves reliability and reduces production losses. The best solution is one that consistently meets process requirements at the lowest reasonable life-cycle cost.

What is the future of humidity-control technology in pharmaceutical manufacturing?

The future of air-treatment technology lies in more intelligent, integrated and energy-efficient environmental-control systems. Sensors and data analytics can help manufacturers identify humidity deviations, equipment deterioration and maintenance requirements before they cause significant production interruptions. Intelligent controls can also adjust system operation according to actual process loads, outdoor conditions and production schedules.

Greater use of heat recovery, improved regeneration strategies and process-specific environmental controls will also shape future manufacturing facilities. Environmental data will become increasingly valuable for quality investigations, trend analysis and demonstrating that manufacturing conditions remain under control. Environmental-control engineering should therefore be incorporated into facility planning from the outset rather than addressed only after commissioning.

What is your message to pharmaceutical manufacturers who still view humidity control primarily as an HVAC issue?

Humidity control should be considered an investment in product quality and process efficiency, not merely an HVAC expense. Environmental conditions can influence raw materials, production consistency and the stability of finished medicines. Poor humidity control may result in powder-handling difficulties, production delays, inconsistent tablets, coating defects and avoidable quality investigations.

Manufacturers should involve their production, quality assurance, engineering and facility management teams in establishing critical process parameters and verifying that systems maintain the required conditions under actual production loads.

At Bry-Air, our approach is to understand each customer’s application before recommending an appropriate environmental-control technology. Ultimately, better humidity control means better control of the manufacturing process. It should therefore be regarded as both a business and quality priority in an industry where product quality and patient safety are paramount.

Wellness, lifestyle and immune-supporting nutrients in breast health

0

 

Breast Cancer Awareness Month provides an opportunity to move beyond awareness of the disease and encourage women to take a more comprehensive approach to their health. Breast cancer prevention and treatment require evidence-based medical care. However, nutrition, physical activity, healthy body weight, adequate sleep and other lifestyle practices also contribute to overall well-being. For women living with or beyond breast cancer, these factors can form an important part of supportive care and survivorship.

It is important, however, to distinguish supporting nutritional and immune function from treating cancer.

Nutrition and normal immune function

The immune system is an intricate network requiring adequate energy, protein, vitamins, minerals and other nutrients for normal physiological function. Poor nutritional status can compromise general health and may be particularly concerning during periods of illness or cancer treatment.

A varied diet therefore remains the foundation of nutritional wellness. Important dietary components include:

Protein: Eggs, fish, poultry, beans, lentils, nuts and seeds provide protein needed for maintenance of muscle and body tissues.

Vitamin C: Found in citrus fruits, peppers, tomatoes and many vegetables and fruits, vitamin C contributes to normal immune function and antioxidant protection.

Vitamin D: Important for bone health, calcium metabolism and normal immune function. Sources include sunlight exposure, selected foods and appropriately indicated supplementation.

Zinc: Found in meat, seafood, eggs, beans, nuts and seeds, zinc contributes to normal immune function and numerous metabolic processes.

Selenium: Found in seafood, eggs, meat, grains and nuts, selenium contributes to normal immune function and protection of cells from oxidative stress.

Folate and other B vitamins: Legumes, vegetables, eggs, whole grains and other foods provide B vitamins involved in normal energy metabolism, cell division and physiological processes.

These nutrients should primarily come from a varied diet. Where dietary intake is inadequate or deficiency is identified, supplementation may have a legitimate role under appropriate professional guidance.

The role of quality nutritional supplements

Quality nutritional supplements can complement a balanced diet by providing selected nutrients and naturally derived nutritional ingredients.

This can be particularly relevant to women whose dietary intake is limited by busy lifestyles, changing nutritional requirements or difficulty achieving dietary variety.

However, supplementation should be individualised. Women undergoing chemotherapy, radiotherapy, endocrine therapy or other cancer treatment should discuss supplements with their oncology team.

Some concentrated supplements, particularly high-dose antioxidant products, may interact with certain treatments.

The responsible wellness position is therefore simple: supplements complement nutrition; they do not replace oncology care.

Lifestyle is part of the prescription for wellness

Nutrition works best when combined with healthy lifestyle practices. Regular physical activity is particularly important. Evidence in breast-cancer survivors associates physical activity with better overall and breast-cancer-specific survival. Exercise can also contribute to physical functioning, sleep, mood and quality of life.

Depending on an individual’s health status and treatment, activities may include walking, swimming, dancing, cycling, resistance exercises or other enjoyable forms of movement.

Maintaining a healthy weight, avoiding tobacco, limiting alcohol, getting adequate sleep and managing chronic stress are additional components of a comprehensive wellness strategy.

A whole-woman approach

Breast health should never be isolated from the health of the whole woman. A practical wellness framework includes:]

Eating a diverse, nutrient-rich diet

Adequate protein and hydration

Regular physical activity

Maintaining appropriate body weight

Adequate sleep and recovery

Stress management and social connection

Avoiding tobacco and limiting alcohol

Appropriate nutritional supplementation where indicated

Regular medical care and recommended breast screening

For women diagnosed with breast cancer, nutritional needs may change during treatment. Some women may require additional calories or protein, while others may need help managing treatment-related eating difficulties. Individual assessment by an oncology team and qualified dietitian can therefore be valuable.

References

  1. National Cancer Institute. Diets, Supplements, and Cancer. NCI.
  2. American Cancer Society. Nutrition and Physical Activity Guideline for Cancer Survivors. ACS.
  3. National Cancer Institute. Breast Cancer Prevention. NCI.

Mrs Chima Ejimofor is the lead partner of Infinite Health Consult, and is available for the purchase of Forever Living products, health talks and wellness seminars. She is based in Lagos, Nigeria. Telephone/WhatsApp: 07033179632, email: infinitehealthconsult@gmail.com

Pharmacy Academy urges urgent action to safeguard medicine security

0

–Holds AGM, investiture of new Fellows November 16–17 in Lagos

 

The Nigeria Academy of Pharmacy (NAPharm) has raised concerns over Nigeria’s alarming dependence on imported medicines, describing it as a threat to national and economic independence and calling for urgent action to safeguard medicine security.

The President and Chairman of NAPharm’s Governing Council, Professor Lere Baale, urged stakeholders to rise to the challenge, warning that the country’s dangerous dependence on imported medicines threatens national security.

He said the nation’s health security was inseparable from its economic security, scientific capability and national sovereignty.

Prof. Baale, who spoke in a statement signed by the Secretary of the Academy, Pharm. Lekan Asuni, ahead of its 2026 Annual General Meeting (AGM) and Investiture of New Fellows, said Nigeria must urgently and decisively address its heavy reliance on imported medicines.

The event, themed, “Pharmacy for National Health Security: Advancing Innovation, Medicine Sovereignty and Sustainable Healthcare,” is scheduled to hold on November 16 and 17, 2026, in Lagos.

“No country can claim genuine independence while remaining dangerously dependent on external sources for its essential medicines, critical pharmaceutical technologies and healthcare innovations.

“Nigeria must move decisively from dependence to capability, from fragmented interventions to integrated solutions, and from healthcare vulnerability to sustainable national resilience. Pharmacy must not merely respond to the future of healthcare; it must help design, shape and secure that future,” he said.

The renowned scholar further stressed that the Academy would continue to champion collaboration among government, academia, pharmaceutical manufacturers, regulatory institutions, healthcare professionals and development partners to translate scientific knowledge into measurable improvements in population health.

According to him, a major highlight of this year’s programme will be the keynote address by the World Health Organisation (WHO) Representative and Head of Mission in Nigeria, Dr Pavel Ursu, on Tuesday, November 17.

He said the theme reflects the Academy’s commitment to positioning pharmacy as a strategic pillar of national development, public health resilience, pharmaceutical innovation and sustainable access to quality medicines.

The formal investiture of new Fellows of the Nigeria Academy of Pharmacy, scheduled to take place at the Old Great Hall, College of Medicine, Lagos University Teaching Hospital (LUTH), Idi-Araba, Lagos, will also be a major highlight of the programme.

The investiture recognises distinguished professional achievements, scholarship, leadership, innovation and outstanding contributions to pharmacy and society.

Professor Baale noted that the honour of Fellowship also comes with a responsibility to advance the profession and contribute to national development.

“Fellowship of the Nigeria Academy of Pharmacy is not simply an honour to be received; it is a responsibility to be discharged. Our Fellows must be architects of solutions, champions of innovation, mentors of future generations and courageous voices for policies that improve the health and well-being of Nigerians,” he said.

NAPharm also called for collective action to achieve universal health coverage, stressing that medicine security and sustainable healthcare could not be achieved through isolated interventions.

It said these goals required a coordinated national commitment to pharmaceutical research and development, local medicine production, workforce development, technology adoption, stronger health systems and policies that encourage investment and innovation.

The Academy said the 2026 AGM and Investiture would reinforce the need to make medicine sovereignty and health security national priorities, noting that pharmaceutical innovation remained essential to Nigeria’s future.

 

A patient taking rifampicin notices that her urine, sweat and tears

5

PANS QUIZ

1. A patient taking rifampicin notices that her urine, sweat and tears have turned reddish-orange. What is the most likely explanation?
A. Drug excretion through body fluids
B. Increased bilirubin production
C. Reduced renal filtration
D. Haemoglobin breakdown

2. A patient develops a persistent dry cough after starting an antihypertensive medication. Which substance accumulates and contributes to this adverse effect?
A. Angiotensin II
B. Renin
C. Aldosterone
D. Bradykinin

3. Taking tetracycline antibiotics together with milk can reduce the absorption of the antibiotic because calcium forms complexes with the drug.
True
False

4. Naloxone reverses opioid-induced respiratory depression by competitively activating opioid receptors.
True
False

Treat suicidal behaviour as public health concern, psychiatrist urges FG

0
Treat suicidal behaviour as public health concern, psychiatrist urges FG
Dr. Udoka Onyechere

A Forensic Psychiatrist, Dr Udoka Onyechere, has urged the Federal Government to adopt a public health approach to suicidal behaviour by decriminalising attempted suicide and prioritising mental healthcare for affected individuals.

Onyechere, who is completing her residency in Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust (CNTW), made the call in an advocacy article on Tuesday in Lagos.
She stressed the need to replace punishment with compassion, medical assessment and appropriate mental healthcare.

Onyechere serves as Officer for Strategic Priorities for Nigerian Psychiatrists in the United Kingdom (NPUK), a Royal College of Psychiatrists Diaspora group, and is a member of the Nigeria Suicide Prevention Advocacy Working Group.

She described attempted suicide as a manifestation of severe psychological distress requiring medical attention rather than criminal punishment.

She said criminalising attempted suicide could deepen stigma, discourage distressed individuals from seeking help and worsen the challenges faced by affected families.

“Suicidal distress is a wound to be tended, not a wrong to be punished. You cannot punish someone out of pain; you can only help them find their way through it,” she said, quoting Dr Hal Abdullahi, President of Nigerian Psychiatrists in the United Kingdom.

Onyechere noted that Nigeria’s Criminal Code and Penal Code still prescribe imprisonment, fines or both for attempted suicide.

According to her, the provisions are colonial-era laws that should be replaced with a more humane approach, particularly as Britain decriminalised attempted suicide in 1961.

She said the Senate’s passage of the National Suicide Prevention Bill 2026 (SB 730) at second reading on Oct. 13 was an important step towards reform.

The bill, sponsored by Sen. Asuquo Ekpenyong, seeks to replace criminal sanctions with crisis intervention, medical assessment, referral, rehabilitation and follow-up care.

Onyechere cited World Health Organisation (WHO) figures presented during the Senate debate, which indicated that about 16,000 Nigerians died by suicide annually.

She warned that criminalisation could reinforce misconceptions about depression and other mental health conditions, often dismissed as laziness, spiritual weakness or lack of faith.

She also cited the support of the Association of Black Psychiatrists UK, whose president, Dr Mosun Fapohunda, described the proposed reform as an important step towards protecting vulnerable individuals.

Onyechere further quoted Dr Shahid Latif, Chair of the Royal College of Psychiatrists Diaspora Groups Committee, as saying that criminalisation could deepen stigma and discourage people from seeking help.
She urged lawmakers to ensure the swift passage of the bill, while encouraging Nigerians to support friends and relatives experiencing emotional distress.

Quoting an Igbo proverb, “Onye aghala nwanne ya” (Let no one abandon their brother or sister), she urged Nigerians to show understanding and support to people experiencing psychological distress.

“For everyone in suicidal distress, one road should lead to a clinic, a listening ear, a treatment plan and a way back. It should not lead to a police station and a charge sheet or shame.

“A nation shows its humanity in how it meets people at their most broken, not with handcuffs but with open arms,” she said. (NAN)

Ilomuanya wins May & Baker Professional Service Award

0

 

Prof. Arinola Joda, receiving the Dummy Cheque on behalf of the awardee, who was unavoidably absent the conference.

Professor Margaret Ilomuanya of the Faculty of Pharmacy, University of Lagos, is the winner of the 2026 edition of the May and Baker Professional Excellence Service Award in Pharmacy.

She was declared the winner at the 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN) held in Awka, Anambra State, after beating many other contestants to the prestigious award.

The May & Baker Professional Excellence Service Award in Pharmacy, which was instituted in 2005, is one of the most prestigious awards in the Pharmacy profession in Nigeria.

The award, which comes with a plaque and certificate, also has a N1.5 million prize tag.  It was established to recognise the contributions and achievements of stakeholders in the pharmaceutical industry in Nigeria.

Professor Margaret Ilomuanya

 

 

While presenting the certificate at the closing banquet of the Ijele 2026, a former Director General of the Standard Organisation of Nigeria, Dr Joseph Odumodu, commended Prof. Ilomuanya for her contributions to the advancement of the pharmacy profession. He urged her not to relent in her oars.

In his brief remarks during the presentation of the award, the Managing Director of May & Baker PLC, Pharm. Patrick Ajah restated the company’s commitment to promoting professional excellence.

“We believe in rewarding innovation and dedication that drive the growth of the pharmaceutical sector”, Pharm. Ajah said, adding that the company’s commitment has made it possible to increase the monetary value of the award from N1m to N1.5m to strengthen its promotion of professional excellence service in the industry.

Meanwhile, Pharmanewsonline checks have shown that pharmacists in academia have dominated the award in recent years, winning it in 2021, 2022, 2023 and 2024 consecutively. A former National Chairman of the Association of Pharmacists in Academia (NAPA), Prof. Martins Emeje, clinched the award in 2021 in Port Harcourt; Deputy Vice-Chancellor (Academic, University of Benin, Professor Ray Ozolua, also won the award in 2022 in Jos. Prof. Emmanuel Ibezim won it in 2023 in Gombe; former Dean of the Faculty of Pharmacy, University of Ibadan, Prof. Toyin Odeku won the award in 2024 in Uyo.

The trend was, however, broken in 2025, when KIMKY Pharmaceuticals and Enterprises, managed by Kim Bot, who was the Director General of the Plateau State Drugs and Medical Commodities Management Agency, won it in 2025.  Pharmacists in Academia may have taken over again with the emergence of Prof. Ilomuanya as the 2026 winner of the prestigious award

 

No new Ebola cases 21 days after imported infection – NCDC

0
The Nigeria Centre for Disease Control and Prevention (NCDC) says the Federal Government’s release of N10 billion is intended to strengthen the country’s overall health security system, not solely for Ebola preparedness amid public debate.
An Image of NCDC Logo

The Nigeria Centre for Disease Control and Prevention (NCDC) says Nigeria has recorded no new cases of Ebola virus disease, 21 days after an imported case involving a traveller from Uganda was confirmed in the country.

The agency said 34 of the 62 contacts identified after the case was confirmed have completed their 21-day monitoring period, while the remaining 28 are still under surveillance.

The Director-General of NCDC, Dr Jide Idris, disclosed this in a National Health Security Update titled, “Follow-up Address: 21 Days Since Confirmation of Imported Ebola Case.”

He explained that being identified as a contact does not mean an individual has contracted the disease, noting that the monitoring process is designed to facilitate early detection of symptoms and ensure a timely public health response.

“The 21 days since the first case was confirmed must not be confused with the separate monitoring period for each contact,” he said.

Idris stressed the importance of early recognition of Ebola symptoms, particularly as the disease may initially present with signs similar to those of common illnesses.

He urged healthcare workers in public and private health facilities to remain vigilant, routinely enquire about patients’ travel history and possible exposure, observe appropriate infection prevention and control measures, and promptly notify public health authorities of suspected cases.

He also called on members of the public to remain alert and report suspected infections, assuring that the agency would continue to investigate credible alerts, communicate verified findings and sustain response activities until all necessary public health measures are completed.

Pharmanewsonline reports that Ebola spreads through direct contact with the blood or other body fluids of an infected person who is symptomatic, or contaminated materials. Anyone who develops symptoms following a possible exposure should avoid contact with others and call the NCDC toll-free line on 6232 for guidance before visiting a health facility.

Meanwhile, Idris drew attention to other infectious diseases that tend to pose increased public health concerns during the dry season, urging healthcare workers and state authorities, particularly in high-risk areas, to strengthen surveillance and preparedness.

He identified dengue fever and chikungunya in Sokoto and Zamfara states, cerebrospinal meningitis in northern states, and diphtheria, which continues to threaten children who are not fully immunised, among the diseases requiring heightened vigilance.

“Dengue fever has been confirmed in Sokoto and Zamfara States, and Chikungunya in Sokoto State. Our teams continue to monitor the evolving situation and support affected states,” he disclosed.

The NCDC boss cautioned against assuming that every fever is malaria, explaining that dengue and chikungunya can also present with fever, headache, body aches and joint pain.

He noted that dengue could become life-threatening if its warning signs are not promptly recognised and managed. Such signs include persistent fever, particularly when accompanied by a rash, vomiting or severe joint pain. Severe abdominal pain, repeated vomiting, bleeding and difficulty breathing, he warned, require urgent medical attention.

He advised anyone who suspects dengue infection to seek immediate medical attention at a healthcare facility.

Idris further explained that the mosquitoes responsible for transmitting dengue and chikungunya are often active during the day, urging residents to take preventive measures by draining stagnant water, covering water-storage containers, clearing discarded tyres and other potential mosquito breeding sites, and protecting themselves against mosquito bites.

Akwa Ibom PSN commends Gov Eno over approval of Pharmacist Consultant

0
Akwa Ibom PSN commends Gov Eno over approval of Pharmacist Consultant
Pastor Umo Eno, Akwa Ibom State Governor

 

The Pharmaceutical Society of Nigeria (PSN), Akwa Ibom State Chapter, has commended Governor Umo Eno over the approval of the Pharmacist Consultant Cadre in the state civil service, describing it as a landmark achievement that will advance specialist pharmacy practice, strengthen healthcare delivery and enhance pharmacists’ career progression.

The approval, formalised through Akwa Ibom State Government Establishments Circular No. 5/2026, issued by the Office of the Head of Civil Service and effective from October 2026, establishes a formal career structure for pharmacists with specialist competencies in the state public service.

In a statement made available through its State Chairman, Pharm. Nsikak Effiong, a Fellow of the Postgraduate College of Pharmacy and consultant pharmacist, the society expressed profound appreciation to Governor Eno for his administration’s approval and support for the adoption of the cadre, describing the development as a demonstration of commitment to professional advancement and quality healthcare delivery.

The PSN acknowledged that the approval was the outcome of sustained advocacy, consultations and engagements involving pharmacists, the society’s leadership and successive administrations in the state. It, however, commended Governor Eno’s administration for providing the needed support to bring the long-standing aspiration to fruition, describing the development as a significant breakthrough and a reflection of the governor’s commitment to listening to professional bodies, addressing legitimate career concerns and creating an enabling environment for the growth of healthcare professionals.

The society said the governor’s intervention had earned him the gratitude and commendation of pharmacists across the state.

It also extended special appreciation to the Head of the Akwa Ibom State Civil Service, Mrs Elsie Peters, for her supportive disposition towards pharmacists and contribution to advancing the professional interests of the pharmacy community.

Effiong acknowledged her understanding of the profession, constructive engagement and support for pharmacists’ aspirations, which he said contributed to the realisation of the landmark achievement. The PSN also appreciated other government officials and relevant stakeholders whose cooperation and contributions helped facilitate the approval.

According to the statement, the development followed sustained professional advocacy and strategic engagement by the PSN leadership with relevant government authorities to secure institutional recognition for specialist pharmaceutical practice.

The Pharmacist Consultant Cadre was previously approved by the National Council on Establishments at its 41st meeting, held in Asaba from 4 to 8 November, 2019, before its adoption at the federal level through a Federal Civil Service circular dated 11 September, 2020.

Its adoption by the Akwa Ibom State Government provides a structured career pathway for pharmacists in the state civil service, aligning their professional advancement with the recognition accorded to specialist expertise.

Under the approved structure, the cadre comprises three levels: Consultant Pharmacist at Salary Grade Level 15; Consultant Pharmacist Special Grade II at Salary Grade Level 16; and Consultant Pharmacist Special Grade I at Salary Grade Level 17.

The PSN said the development was expected to strengthen specialist pharmaceutical services, encourage professional development, improve career advancement opportunities and support the retention of experienced pharmacists within the state’s healthcare system.

It added that formal recognition of specialist pharmacists would enable the health system to better harness their expertise in clinical decision-making, medication safety, rational medicine use and patient-centred care, with potential benefits for health outcomes.

The society described the approval as more than an administrative milestone, saying it represented an investment in professional excellence, specialist healthcare delivery and the future of pharmacy practice in the state.

It called for sustained collaboration among the PSN, the state government, relevant ministries, healthcare institutions and other stakeholders to ensure effective implementation of the approved cadre.

A cross-section of Akwa Ibom State PSN delegates and government officials, flanked by the Head of the Akwa Ibom State Civil Service, Mrs Elsie Peters, and PSN Chairman, Akwa Ibom State Chapter, Pharm. Nsikak Effiong (both in the middle), during a courtesy visit by the society to the office of the Head of the Civil Service, Akwa Ibom State.

The society congratulated pharmacists in the Akwa Ibom State Civil Service on the development, expressing optimism that the new structure would promote professional recognition, strengthen specialist pharmaceutical practice and enhance pharmacists’ contribution to healthcare delivery.

 

 

 

DP World Healthcare, Miraflash partner to boost medicine access nationwide

0

 

DP World Healthcare, Miraflash partner to boost medicine access nationwide
DP World Healthcare Nigeria and its partner formalise their strategic partnership through the signing of the agreement.

DP World Healthcare Nigeria has partnered with indigenous pharmaceutical manufacturer Miraflash Nigeria Limited to strengthen pharmaceutical distribution, expand access to locally manufactured medicines DP World and improve healthcare supply chain efficiency across Nigeria.

The partnership was formalised through the signing of a Memorandum of Understanding (MoU) on 14 October, marking Miraflash’s integration into DP World Healthcare’s nationwide pharmaceutical distribution network.

Speaking at the signing ceremony, Pharm. Chief Moses Oluwalade, managing director of Miraflash Nigeria Limited, said the collaboration would help address longstanding distribution and infrastructure challenges that have limited the company’s growth despite more than two decades of producing quality medicines.

According to him, DP World Healthcare’s extensive logistics capabilities, warehousing infrastructure and operational expertise provide the ideal platform for expanding Miraflash’s reach and ensuring wider availability of its products across the country.

“Effective distribution is as important as manufacturing in healthcare delivery. Medicines require strict storage and handling conditions to maintain their quality and efficacy. Through DP World Healthcare’s warehouse network spanning Nigeria’s six geopolitical zones, we expect improved market accessibility, faster delivery timelines and broader nationwide coverage,” Oluwalade stated.

Also speaking at the event, Naveen Pala, managing director of DP World Healthcare Nigeria, described Miraflash as a reputable indigenous pharmaceutical company whose product portfolio complements DP World Healthcare’s expanding healthcare business.

He emphasised DP World Healthcare’s more than 25 years of proven expertise in pharmaceutical distribution, regulatory affairs, demand generation, marketing support, cold-chain logistics and pharmaceutical warehousing, positioning the company as a trusted one-stop partner delivering integrated healthcare solutions.

“Miraflash has built a strong reputation for quality and innovation in pharmaceutical manufacturing. We are delighted to partner with the organisation and support its next phase of growth through our robust distribution and healthcare infrastructure,” Pala said.

He disclosed that DP World Healthcare currently operates 11 pharmaceutical-grade warehouses across Nigeria and plans to expand its footprint to between 15 and 20 facilities over the next two years.

According to him, the company’s investment in advanced cold-chain capabilities and decentralised distribution infrastructure is designed to improve product availability, accelerate delivery times and enhance service quality nationwide.

Pala further emphasised that the partnership presents a significant opportunity for Miraflash to scale its manufacturing operations, broaden its product portfolio and strengthen its market presence, while also supporting DP World Healthcare’s commitment to advancing Nigeria’s pharmaceutical value chain.

The signing ceremony was attended by senior executives from both organisations, including Gugulethu Mayisela, vice-president, Finance – Healthcare Africa; Mani Balasubramanian, vice-president, Finance – Healthcare West Africa; Shettipalli Chakradhar, head of finance; and Ananth Sigadapu, business unit head, representing DP World Healthcare Nigeria.

Miraflash was represented by Bode Ayenibiowo, marketing manager, and Yemi Akinwande, quality assurance manager.

Empowering pharmacists for healthier futures

0

Why the profession needs both enabling systems and the power built from within

Empowering pharmacists for healthier futures
Dr Lolu Ojo

The future of Pharmacy will depend not only on the authority, recognition and opportunities society gives pharmacists, but also on the competence, character and relevance pharmacists build for themselves. Nigeria needs both forms of empowerment if the profession is to deliver better health outcomes and help shape the future of healthcare.

The theme of the 2026 WORLD PHARMACISTS DAY, “Empowering Pharmacists for Healthier Futures”, invites a question that the profession must answer honestly: who empowers the pharmacist? Is it government, the Pharmacy Council of Nigeria, the Pharmaceutical Society of Nigeria, universities, employers, patients or technology? Or does the pharmacist also bear responsibility for his or her own empowerment?

Empowerment is often understood as the granting of authority, freedom, confidence or strength to act. In Pharmacy, this has two inseparable dimensions. There is empowerment from without: the laws, policies, education, recognition, remuneration and working environment that enable pharmacists to practise effectively. There is also empowerment from within: the competence, character, confidence, innovation and capacity that pharmacists deliberately develop in themselves.

The future of Pharmacy will depend both on the opportunities society gives pharmacists and on the capacity pharmacists build to recognise, create and seize those opportunities. External empowerment creates opportunity; internal empowerment creates capacity. A profession that receives authority without developing the competence to use it will squander opportunity. Conversely, a profession that develops exceptional capacity while remaining structurally excluded will eventually become frustrated. Pharmacy needs both.

The world is changing and pharmacy must change with it

Healthcare is passing through one of the most consequential periods in its history. Artificial intelligence is transforming knowledge work. Digital health is changing how patients access information and care. Precision medicine is challenging the traditional one-size-fits-all approach to treatment. Populations are ageing, non-communicable diseases are increasing, antimicrobial resistance threatens medicines that once transformed human survival, and recurring supply-chain disruptions have reminded nations that medicine security is inseparable from national security.

Patients have changed as well. The patient of yesterday came to the healthcare professional primarily for information. Today’s patient may arrive after consulting Google, social media, an artificial intelligence platform, friends, an online pharmacy and perhaps an influencer. Knowledge remains fundamental, but possession of information alone can no longer be the pharmacist’s defining advantage.

That advantage must increasingly lie in judgement, interpretation, clinical reasoning, communication, ethical leadership, trust, and the ability to convert pharmaceutical knowledge into better outcomes for human beings. Technology can retrieve information, identify interactions, analyse vast amounts of data and automate routine processes. Healthcare, however, ultimately concerns a human being, not merely a medicine or a dataset.

The pharmacist of the future must therefore move beyond being predominantly a custodian of medicines to becoming a custodian of medication outcomes. This is not a rejection of the profession’s traditional responsibilities. It is their logical completion.

From dispensing medicines to delivering outcomes

For generations, pharmacy established its importance around medicines: their discovery, formulation, manufacture, procurement, storage, distribution and dispensing. These functions remain indispensable. Yet the question society increasingly asks is no longer simply, “Who supplied the medicine?” It is, “Did the medicine make the patient better?”

That apparently small change has enormous implications. The pharmacist must be concerned not only that the correct medicine reaches the correct patient, but also that it produces the best attainable outcome, at an affordable cost and with minimal harm. Did blood pressure improve? Was diabetes better controlled? Was an adverse drug reaction prevented? Was adherence improved? Was unnecessary hospitalisation avoided?

This moves pharmacy from a predominantly product-centred orientation towards an outcome-centred profession. Nigeria does not merely need more medicines; it needs better health outcomes from the medicines it already consumes. Pharmacists should be visible in prevention, primary healthcare, medication optimisation, chronic disease management, pharmacovigilance, public health, research, manufacturing, medicine security, policy and technology. Pharmaceutical expertise should be present wherever decisions about medicines and health outcomes are made.

The difficult question is whether pharmacists are adequately preparing for these roles or merely demanding recognition for them. Recognition without demonstrable value is fragile. Sustainable professional influence rests on evidence that patients, institutions and the health system perform better because pharmacists are involved.

Empowerment from without

There are legitimate external barriers to the advancement of Pharmacy, and they should not be minimised. A pharmacist cannot practise to the full extent of competence where laws and policies unnecessarily constrain professional practice. Pharmacists cannot maximise their contribution where reimbursement systems recognise products but fail to recognise cognitive and clinical services. They cannot fully contribute where multidisciplinary structures exclude pharmaceutical expertise from decisions in which it is indispensable. Young pharmacists cannot become globally competitive if their education remains disconnected from scientific, technological and practice change.

Government, regulators, universities, healthcare organisations, employers and professional bodies therefore have clear responsibilities. Nigeria needs progressive regulation, stronger pharmacy education, competency-based continuing professional development, appropriate recognition and remuneration for professional services, meaningful integration of pharmacists into primary healthcare and national health programmes, expanded collaborative-practice opportunities, and greater investment in research, innovation and local pharmaceutical manufacturing.

Professional recognition must also be matched by responsibility and accountability. Expanded authority is most defensible when the profession can demonstrate rigorous standards, ethical conduct and measurable benefits to patients. Advocacy remains necessary, but advocacy is strongest when it is supported by results.

There is, however, a danger: a profession can become so preoccupied with what others have failed to do for it that it stops asking what it has failed to do for itself. This is why empowerment from within is equally important.

Empowerment from within

Some doors must be opened for pharmacists, but some doors will open only when pharmacists become impossible to ignore. There is a form of power that no government can legislate into existence: the power of competence, character, relevance, innovation, economic contribution, leadership and the consistent ability to solve problems that matter to society.

A pharmacist who continually upgrades professional knowledge is building personal power. A pharmacist who develops competence in digital health and artificial intelligence is preparing for emerging practice. A community pharmacist who transforms a premises from merely a place where medicines are sold into a genuine healthcare destination is empowering the profession. A hospital pharmacist who demonstrates measurable improvements in medication outcomes strengthens the case for pharmaceutical care. An industrial pharmacist who builds a sustainable manufacturing enterprise advances medicine security. An academic pharmacist whose research solves real health problems creates societal value.

The young pharmacist who develops competence beyond the minimum required for registration is investing in the future. The pharmacist whose integrity is so established that his or her word can be trusted is accumulating perhaps the most valuable professional capital of all: credibility.

This internal form of empowerment does not excuse institutional failure. It ensures that pharmacists are prepared to use opportunity when it comes, and capable of creating opportunity when it does not. (Continues next edition)

By Pharm. (Dr)  Lolu Ojo, BPharm, MBA, PharmD, FPCPharm, FPSN, FNAPharm

Pharmacists urged to take lead in clinical research, drug trials

0

 

Pharmacists urged to take lead in clinical research, drug trials
Director of Pharmacist, LASUTH, Pharm (Dr) Modupe Oyawole

Pharmacists have been urged to move beyond their traditional roles of medicine dispensing and take leading positions in clinical research and drug trials to strengthen patient safety, improve healthcare outcomes and advance evidence-based medicine in Nigeria.

The Director of Pharmacy, Lagos State University Teaching Hospital (LASUTH), Pharm (Dr) Modupe Oyawole, made the call during a plenary session at the Pharmaceutical Society of Nigeria’s 99th Annual National Conference, Ijele ’26, in Awka, Anambra State.

In a presentation titled “Clinical Research and Trials Ecosystem: The Roles of Pharmacists”, Oyawole said pharmacists have critical responsibilities across the entire clinical research process, from identifying research questions and evaluating medicines to ensuring patient safety and regulatory compliance.

She explained that clinical research and clinical trials, although related, are not the same, noting that clinical research involves studying people, health data or tissue samples to understand health and disease, while clinical trials specifically tests new treatments and evaluated their effects on human health outcomes.

According to her, clinical research encompasses observational studies, interventions, surveys and behavioural studies aimed at expanding medical knowledge, whereas clinical trials focus on evaluating the safety and effectiveness of new treatments, including medicines, vaccines, medical devices and therapies.

She stressed the distinction with the statement, saying “every clinical trial is a clinical research, but not all clinical research is a clinical trial”.

Oyawole explained that a clinical trial was only one component of a much broader evidence-generation system that begins with the discovery of a promising molecule, proceeds through preclinical investigations and clinical trials, and continues through regulatory assessment and real-world evidence.

Highlighting the first major responsibility of pharmacists, she said they should be able to identify research questions from medication-related problems encountered in their daily professional practice. She said, “Pharmacists see medication-related problems every day. Research begins when we turn observation into a rigorous question”.

According to her, pharmacists must bring their knowledge of medicines to bear throughout the clinical trial process, particularly in ensuring appropriate medicine handling, dosing, safety monitoring and adherence, even as she highlighted their responsibility in building a bridge between patients and research evidence through counselling, adherence support and medication safety.

She explained that pharmacists could help research participants understand their medicines, treatment expectations and practical requirements, while identifying barriers to adherence, supporting treatment persistence and documenting medicine use.

On medication safety, she identified medication reconciliation and the identification of drug-related problems as important contributions pharmacists can make to protect participants and improve research quality.

Oyawole further identified pharmacokinetics as another important area of pharmacists’ involvement, explaining that their expertise could help establish the relationship between the doses administered, the concentration of a medicine in the body, the exposure of the patient and the resulting clinical response, noting that pharmacists can contribute to pharmacokinetic sampling, dose optimisation, interaction assessment and therapeutic drug monitoring.

The LASUTH Director of Pharmacy also drew attention to pharmacogenomics and its importance in advancing precision medicine, which seeks to establish not just whether a medicine works but the patients for whom it works, the appropriate exposure and the risks associated with its use.

She said “Precision medicine asks not only ‘Does it work, but ‘For whom, at what exposure, and with what risk?”

She however identified several challenges limiting pharmacists’ participation and leadership in clinical research, including inadequate mentorship, insufficient research training, limited funding, poor access to research networks, inadequate research infrastructure, limited leadership opportunities and weak industry-academia collaboration.

She observed that the problem was not the absence of opportunities for pharmacists in clinical research. “The gap is not the absence of a pharmacist role. It is the capacity to occupy that role at scale”, she stated.

To address the challenges, Oyawole outlined five key actions for Nigerian pharmacists, which include generating research, joining research initiatives, building capacity, taking leadership positions and translating research findings into practice.

She maintained that the objective should not simply be to have more pharmacists participating in research activities. “The goal is not to have more pharmacists around research; it is more pharmacists capable of shaping research”, she said.

She charged pharmacists to recognise that their professional responsibility extends beyond their knowledge of medicines to understanding and generating the evidence that establishes their safety, effectiveness and appropriate use, saying “If we as pharmacists are experts in medicines, we must also be experts in evidence about medicines”.

 

Mitigating myths, misinformation about HPV vaccine among Nigerians

0

 

“The vaccine is intended to reduce Nigeria’s population. So I was told by my neighbour,” said Mrs Ireti Adekola. “Do not allow them to give your daughter the vaccine in school,” her neighbour added.

The human papillomavirus (HPV) vaccine, according to the World Health Organisation (WHO), is a safe and highly effective public health measure designed primarily to prevent cervical cancer and other diseases caused by HPV. It works by stimulating the immune system to produce antibodies against specific types of the virus, thereby helping to prevent cervical cancer, other HPV-related cancers and genital warts.

Introduced in Nigeria in October 2023, with the goal of vaccinating more than 16 million girls through mass campaigns in schools, communities and public places, the HPV vaccine has been confronted by widespread myths and misconceptions. These have prevented some parents from allowing their daughters to receive the vaccine, potentially leaving them vulnerable to cervical cancer later in life.

While young adolescent girls aged 9–14 are the primary target group for HPV vaccination in most countries, WHO recommends a one- or two-dose schedule for girls aged 9–14; a one- or two-dose schedule for girls and women aged 15–20; two doses, with a six-month interval, for women older than 21; and at least two doses, and where possible three doses, for immunocompromised individuals, including those living with HIV.

Myths about HPV vaccine

Another mother, Mrs Berky Kanu, opened up about other forms of misinformation she had been exposed to, which influenced her decision not to give consent for her two daughters to receive the vaccine.

“I have heard several times that giving the vaccine to young girls will encourage promiscuity or early sexual activity; that a girl who is morally upright or not sexually active does not need the vaccine; that the HPV vaccine is unnecessary because the girls are too young; and that the HPV vaccine causes infertility or sterility,” she said.

“Although health workers and government officials tell us that these are not true, who do we believe in this situation?” she asked. “This is the main reason I prevented my children from accepting the injection.”

Cervical cancer mortality in Nigeria

In Nigeria, cervical cancer is ranked among the leading cancers affecting women. According to data from the International Agency for Research on Cancer’s GLOBOCAN estimates, cervical cancer remains a significant public health concern in the country.

However, cervical cancer is largely preventable through HPV vaccination, screening and timely treatment of precancerous lesions. Interestingly, the GLOBOCAN data from 2020 to 2024 indicate a consistent decline in estimated cervical cancer mortality in Nigeria. This highlights the possibility of preventing further deaths through improved vaccination, screening, early detection and treatment. From 7,968 deaths in 2020 to 7,093 in 2022, and now 6000 deaths in 2024, which is the latest statistics. The figures underscore the need for sustained interventions to prevent more Nigerian women from dying from a largely preventable disease.

“The loss of about 6,000 Nigerian women yearly from a disease that is preventable is completely unacceptable,” says Muhammad Ali Pate, the Coordinating Minister of Health and Social Welfare, at one of the vaccination campaigns.

“Cervical cancer is mostly caused by HPV, and parents can avoid physical and financial pain by protecting their children with a single dose of the vaccine,” he added.

Dispelling myths and misinformation on HPV vaccination

Contrary to the numerous myths about HPV vaccination propagated by anti-vaccine groups, medical experts have described the claims as misinformation, stressing that the vaccine is an important measure for protecting Nigerian girls against cervical cancer later in life.

As part of efforts to convince mothers of the importance of HPV vaccination and why parents should grant consent for their daughters to receive the vaccine, the Coordinating Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, disclosed publicly that he had consented to his four daughters receiving the vaccine to protect them against cervical cancer in the future.

“As a parent myself, I have four daughters; all of them have had the same HPV vaccine to protect them against cervical cancer. I’d like to implore fellow parents to dutifully ensure that this generation of our girls disrupts the preventable loss of lives to cervical cancer, in addition to other untold hardship, loss and pain,” he pleaded.

Speaking in an exclusive interview with Dr Kehinde Ososanya, a public health physician with the Lagos State Primary Healthcare Board, on how to mitigate misinformation about HPV vaccination in local communities, he noted that maternal health is of utmost importance to the nation because a healthy woman helps to raise a healthy family and build a healthy community.

“That is why the Primary Healthcare Board is very particular about maternal health,” he said, adding that the board places emphasis on preventive measures to prevent diseases that could cut short the lives of mothers and infants.

The public health physician, who acknowledged the existence of myths about HPV vaccination in communities, said awareness campaigns through health education were necessary to counter the misleading information surrounding the vaccine.

While HPV vaccination has been introduced into the routine immunisation programme in the country, he said some parents were still hesitant to bring their daughters for vaccination.

To address the misinformation, he said the Primary Healthcare Board had deployed health officers to educate parents and community members on the importance of HPV vaccination and other healthcare programmes available at primary healthcare centres.

“This is all about creating awareness; it’s all about health education, and it’s all about mingling with our people at the community level so that they understand, in local terms, the importance of primary healthcare, the importance of coming to vaccinate their children or bringing their children for vaccination.

“The importance of coming to the clinics for family planning, the importance of food demonstration, in addition to routine immunisation, and ensuring that you have proper care, you know, amongst other things.

“We have people who are specialised in ensuring that they go into the communities to educate our people. We have community health officers and workers who also do not stay in the health facility, but are found within the communities, ensuring that people are well informed about healthcare and the steps they can take in ensuring that they have good health and good access to quality healthcare,” he explained.

Ososanya, who is the deputy director/service delivery programme manager at the Primary Healthcare Board, further disclosed that HPV vaccines are available free of charge at healthcare facilities across Lagos State for girls aged 9–14, urging mothers to disregard the myths and take their daughters for the vaccination.

He also highlighted other programmes offered at primary healthcare centres, including family planning, food demonstration and routine immunisation.

Initially, he disclosed, the grassroots medical team visited schools, communities and other public places to sensitise the populace about the importance of the vaccine. Beyond this, he said, the team had trained community leaders to serve as local mobilisers, educating residents about activities at primary healthcare centres and encouraging them to maximise the available programmes for healthier lifestyles.

To rid the nation of cervical cancer, he urged mothers, parents and guardians to take their girls for HPV vaccination before it becomes too late. “This is an opportunity to inform our mothers, parents and guardians to permit and ensure that they bring their girls between the ages of 9 and 14 to get the HPV vaccine, which they will get at the primary healthcare centre free of charge, because prevention is better than cure,” he said.

 

Ndukwe elected new PSN national secretary

1
Pharmacist Ndukwe Ama Ndukwe

Pharmacist Ndukwe Ama Ndukwe has been elected National Secretary of the Pharmaceutical Society of Nigeria (PSN).

Pharm. Ndukwe emerged as the winner of the election at the PSN Annual General Meeting during its 99th Annual National Conference, tagged IJELE 2026, at the International Convention Centre, Awka, Anambra State.

He defeated his co-contestant, Pharm Kingsley Akwunife to clinch the seat.

Ndukwe takes over from Pharm. Gafar Madehin who takes a bow after a successful completion of his tenure of three years in office, from 2023 to 2026.

Ndukwe is a former assistant national secretary for both the PSN and Association of Community Pharmacists of Nigeria (ACPN).

Speaking with Pharmanews shortly after being sworn in, the new PSN National Secretary promised to work hard to unify pharmacy. He said “expect a unifying pharmacy by the grace of God. We are going to close ranks”.

 

WHO to address climate change and health at COP31

0

The world Health Organisation (WHO) is set to open the 31st United Nations Climate Change Conference (COP31) with a dedicated Health Day on November 9, 2026, to address the growing impact of climate change on human health.

The world Health Organisation (WHO) is set to open the 31st United Nations Climate Change Conference (COP31) with a dedicated Health Day on November 9, 2026, to address the growing impact of climate change on human health.

The event will bring together health ministers, government representatives and experts to discuss solutions around climate change, air pollution, energy and public health. It will also feature panel discussions and a ministerial roundtable focused on building resilient health systems. According to WHO’s 2025 Health and Climate Change Global Survey, although countries have knowledge of effective climate-health interventions, inadequate funding and implementation remain major challenges.

To bridge this gap, the COP31 Presidency will launch the Antalya Initiative for Health Resilience (AIR), a voluntary initiative designed to help countries share experiences, develop effective policies and strengthen their health systems against climate-related risks.

WHO also disclosed that approximately 3.5 billion people live in areas highly vulnerable to climate change, while air pollution accounts for about seven million deaths globally each year.

WHO’s Head of Climate Change, Energy and Air Quality Unit, Dr Diarmid Campbell-Lendrum, described health as a strong argument for climate action, urging countries to move from knowledge to implementation.

The organisation further revealed that six priority climate-health interventions could save 1.6 million lives annually and generate US$24 in benefits for every US$1 invested. WHO is expected to host more than 60 events at the COP31 Health Pavilion during the two-week conference .

Breastfeed newborns with colostrum, paediatrician urges mothers

0

Breastfeed newborns with colostrum, paediatrician urges mothers

‌⁠⁠​‍‍⁠⁠‍‌⁠‍‍‍​‌‍‌Prof. Edamison Temiye, a consultant paediatrician at the Lagos University Teaching Hospital (LUTH), has urged mothers to breastfeed newborns, particularly with colostrum, the first breast milk because of its protective benefits against infections.

Temiye gave the advice in an interview with the News Agency of Nigeria (NAN) on Thursday in Lagos.
He said that colostrum contained essential proteins, water and antibodies that helped protect newborns.

Temiye explained that colostrum, usually produced within the first three days to one week after delivery, provided sufficient nutrients for newborns during their early days.

“At birth, the amount of milk produced is usually very small, but the colostrum is enough to satisfy the baby. It is rich in protein, water and immunity to protect the baby,” he said.

The paediatrician said breast milk production depended largely on the baby’s demand, noting that regular breastfeeding stimulated increased milk production.

“Breast milk is produced on demand. If the baby demands regularly and sucks regularly, the mother will produce more milk,” he said.

Temiye said failure to empty the breasts could cause engorgement, pain and discomfort, making breastfeeding uncomfortable for mothers.

He also dismissed the belief that breast milk left in the breast for several days became contaminated, describing such claims as misconceptions.

“The milk is inside the mother’s breast and is perfectly preserved there. It cannot become contaminated simply because the baby has not sucked for some days,” he said.

On weaning, Temiye explained that milk production gradually reduced when a mother stopped breastfeeding, as the body adjusted to the absence of the baby’s demand.

He said mothers could initially experience breast fullness, pain, warmth and discomfort after stopping breastfeeding.
“By the third day, the body begins to recognise that nobody is drinking the milk anymore and starts reducing production. Within one week, the engorgement should subside,” he said.

He added that breastfeeding could stimulate milk production again if a baby resumed sucking after a period of stopping. (NAN)

Which enzyme is primarily responsible for the metabolism of codeine…

8

Which enzyme is primarily responsible for the metabolism of codeine

PANS QUIZ

1. Which enzyme is primarily responsible for the metabolism of codeine into morphine, its more potent opioid metabolite?
A. CYP1A2
B. CYP2D6
C. CYP3A4
D. CYP2C19

2. A drug with a narrow therapeutic index generally requires closer monitoring because a small difference between its therapeutic and toxic concentrations can have significant clinical consequences.
True
False

3. Which of the following are recognised mechanisms by which bacteria develop resistance to antibiotics? Select all that apply.
A. Alteration of the antibiotic’s target site
B. Increased permeability of the bacterial cell membrane
C. Active efflux of antibiotics from bacterial cells
D. Enzymatic destruction or modification of the antibiotic

4. The first-pass effect can reduce the oral bioavailability of a drug before it reaches systemic circulation.
A.True
B.False

PCN shuts 5,000 Illegal outlets in 2026

0

-Vows crackdown on FCT operators

PCN shuts 5,000 Illegal outlets in 2026
A speaker addressing participants at the 99th PSN Annual National Conference in Ile-Ife.

The Pharmacy Council of Nigeria (PCN) has intensified its nationwide regulatory enforcement, shutting down more than 5,000 pharmaceutical facilities across 11 states in 2026, over various violations of regulations.

The Registrar of the Council, Pharm. Babashehu Ahmed, disclosed this while speaking at the plenary session of the ongoing 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN), tagged IJELE 2026, at the International Convention Centre, Awka, Anambra State.

Ahmed, who spoke on “Building Stronger Health Systems through Pharmaceutical Governance and Regulation,” said the enforcement exercise was part of efforts to sanitise Nigeria’s drug distribution system and ensure that pharmaceutical premises operate within approved regulatory standards.

Providing details of the council’s enforcement activities, he disclosed that 9,908 facilities were visited between 29 March and 16 October, 2026, including 1,600 pharmacies and 5,698 patent and proprietary medicine vendors.

He said the exercise uncovered widespread violations among operators, particularly pharmacies operating without pharmacists on duty and patent medicine vendors conducting activities outside the scope of their licences.

According to him, 771 of the 1,600 pharmacies visited were found to have various compliance deficiencies, including situations where pharmacists were absent while sales personnel were left to attend to customers.

He also disclosed that 2,610 patent and proprietary medicine outlets had never been registered and were operating illegally, adding that they were permanently shut down, adding that another 3,257 licensed patent and proprietary medicine vendors were found to be operating outside the scope of their licences and were also closed.

The registrar said the council had taken further steps to investigate serious violations, with 292 premises subjected to investigation, comprising 51 pharmacies and 241 patent and proprietary medicine vendors.

He stressed that regulatory enforcement was not simply about visiting facilities and announcing closures but also involved sustained investigations and legal action to ensure that offenders were held accountable.

Ahmed disclosed that the council had generated about 60 litigations in the course of its enforcement activities and spent approximately N50 million on legal proceedings within the year, adding that the council had secured favourable outcomes in the cases mentioned, despite the financial burden of defending its regulatory authority in court.

He, however, maintained that the responsibility for effective regulation should not rest solely on the national council, urging state governments and relevant regulatory committees to strengthen enforcement within their jurisdictions.

He disclosed that the PCN released N450 million to Pharmaceutical Inspection Committees and Patent and Proprietary Medicine Committees between January and September 2026 to support their regulatory responsibilities across the states.

Ahmed expressed concern that illegal pharmaceutical operations continued to thrive despite the existence of these structures and the financial support provided by the council. He questioned the effectiveness of some state committees, particularly where illegal premises continued to operate without appropriate regulatory intervention.

On the operational challenges confronting the PCN, the registrar said the council maintained 44 offices across the country and faced substantial expenditure on electricity and other essential services.

He disclosed that diesel alone cost the council approximately N12.5 million monthly, while electricity charges for its Abuja headquarters under Band A is between N3 million and N3.5 million monthly.

He identified significant differences in the level of illegal pharmaceutical activities across states, citing figures from the council’s enforcement assessment which showed that some states had considerably higher levels of violations than others.

Ahmed said the council had also encouraged state governments to use funds made available to their regulatory structures for location approvals, routine inspections and enforcement activities.

He commended Lagos, Anambra and Nasarawa states for commencing enforcement exercises, urging other states to follow their example, saying coordinated action by the 36 states and the Federal Capital Territory, alongside the national council’s enforcement activities, will significantly strengthen pharmaceutical regulation.

He said the PCN’s regulatory responsibility covered all aspects of the pharmaceutical sector, from manufacturing and importation to distribution, retailing and patent medicine operations.

The registrar maintained that regulation was the connecting force among the six building blocks of a functional health system identified by the World Health Organisation, including leadership and governance, health workforce, essential medicines, service delivery, health information and sustainable financing.

He said the effectiveness of the pharmaceutical sector should ultimately be judged by the confidence Nigerians have in the medicines they use, the professionals who attend to them and the institutions responsible for protecting public health.

“No single institution can hold up all the six building blocks alone”,  Babashehu said, stressing that building a stronger health system required collective responsibility among regulators, policymakers, pharmacists, industry leaders, academics and other stakeholders.

Hand, foot and mouth disease: Prevention and management

0
Hand, foot and mouth disease: Prevention and management
DC Health, Government of the District of Columbia. Hand, Foot and Mouth Disease Prevention.

Hand, foot and mouth disease (HFMD) is a common viral infection that mainly affects babies and children under five years of age, although older children and adults can also develop the disease. It is usually mild and clears up on its own within seven to ten days. However, it can cause considerable discomfort, especially when painful mouth sores make eating and drinking difficult. Understanding how the disease spreads, recognising its symptoms and adopting appropriate preventive measures are important for protecting children, families and communities.

The disease is caused by viruses belonging to the enterovirus group. Coxsackievirus A16 is a common cause, although other viruses, including enterovirus A71, can also cause the illness. The disease spreads through close contact with an infected person, saliva, fluid from skin blisters, respiratory droplets released during coughing or sneezing, and contact with faeces. Infection can also occur when people touch contaminated objects and surfaces, such as toys, door handles, tables and feeding utensils, before touching their mouths, noses or eyes.

The first symptoms often include fever, sore throat, tiredness and loss of appetite. Painful sores may subsequently develop inside the mouth, on the tongue and around the gums, while a rash, sometimes accompanied by small blisters, may appear on the palms of the hands, soles of the feet and other parts of the body, including the buttocks. Despite its name, the disease does not always affect only the hands, feet and mouth. Symptoms usually appear three to six days after infection, and some people, particularly adults, may experience mild symptoms or none at all while still contributing to the spread of the virus.

 

Prevention

Good personal hygiene remains one of the most effective ways to prevent the spread of HFMD. Children should be taught to wash their hands thoroughly with soap and clean running water, particularly after using the toilet, changing nappies, wiping their noses and before eating or preparing food.

Parents and caregivers should supervise young children to ensure that they wash their hands properly. Alcohol-based hand sanitisers may be useful in some situations, but they should not replace handwashing with soap and water, especially when the hands are visibly dirty.

Frequently touched surfaces, toys, feeding utensils and shared play equipment should be cleaned and disinfected regularly. Children and adults should avoid sharing cups, spoons, towels and other personal items with infected people. Children who are unwell should stay away from school, nursery or childcare settings when they have a fever, feel too ill to participate in normal activities or cannot control drooling caused by mouth sores. Parents should follow local public health guidance on when children can safely return.

Teaching children to cover their mouths and noses when coughing or sneezing, dispose of used tissues properly and avoid close contact with infected people can also reduce transmission. Caregivers should wash their hands carefully after changing nappies or cleaning up bodily fluids. There is no widely available routine vaccine that protects against all the viruses responsible for HFMD, making good hygiene and environmental cleanliness essential preventive measures.

Treatment

There is no specific medicine that cures ordinary hand, foot and mouth disease because it is caused by a virus. Antibiotics are ineffective against the infection, although a healthcare professional may prescribe them if a separate bacterial infection develops.

Treatment therefore focuses on relieving symptoms, maintaining adequate fluid intake and preventing dehydration. Children should be encouraged to drink plenty of fluids, including water and other suitable drinks. Cool drinks and soft foods may be easier to swallow when mouth sores are painful, while acidic drinks, such as orange juice, and spicy or salty foods should be avoided if they worsen the discomfort.

Paracetamol may help relieve fever and pain when administered according to the child’s age, weight and the instructions on the product label or the advice of a healthcare professional. Ibuprofen may also be suitable for some children, but it should not be given to a dehydrated child. Aspirin must not be given to children unless specifically directed by a specialist. Parents should also avoid giving children un-prescribed mouth gels or sprays, as some products contain ingredients that may be unsafe for young children. A pharmacist or doctor can recommend appropriate ways to manage mouth pain and other symptoms.

Most children recover within seven to ten days without serious complications. Nevertheless, parents and caregivers should seek medical attention if a child cannot drink adequately, passes urine less frequently than usual, develops a persistent high fever, experiences worsening symptoms or appears unusually weak or drowsy. Severe headache, neck stiffness, confusion, difficulty breathing or seizures require urgent medical assessment. These warning signs should never be ignored, as serious complications, although uncommon, can occur.

Local manufacturing and medicine price inflation in Nigeria

0

 

Drug manufacturing plant

There continues to be a vociferous clamour for the Nigerian local pharmaceutical manufacturing space to improve its capacity in order to serve the medicine needs of Nigerians and perhaps the wider African continent. In fact, it was the focal point of deliberations at the 2026 Nigeria Pharma Manufacturers’ Expo held in Lagos. Pharma leaders, such as Dr Fidelis Ayebae, chairman of Fidson, Chief Stella Okoli, CEO of Emzor and Mr Oluwatosin Jolayemi, CEO of Daily Need Industries, spoke to the importance of improving Nigeria’s local pharmaceutical output and its ripple effects on the national economy.

Ayebae’s presentation during the panel session was instructive, as he linked the improvement of the nation’s local manufacturing capacity to economic growth. He argued that Nigeria’s economy could blossom if we begin producing what we consume. He took the challenge beyond the pharmaceutical industry, urging other sectors of the economy to think of manufacturing independence, a situation where we no longer have to depend on other countries for the products we consume, especially pharmaceuticals. He consequently discouraged the saturation of the Nigerian pharmaceutical market with imported medicines from India, while urging Indians to set up manufacturing plants in Nigeria – a development that will boost the national economy and strengthen the naira.

Despite the optimism that permeated the atmosphere at the 2026 Nigeria Pharma Manufacturers’ Expo, it is important to face the reality on the ground. While the DG of NAFDAC and some other stakeholders continue to sell the narrative that Nigeria’s local pharmaceutical manufacturing capacity is now at a 50:50 ratio, the claim seems to be at variance with the daily experiences of the average Nigerian patient who struggles to access quality medications for common ailments like malaria and typhoid.

Besides the fact that some of these medications are no longer very effective in the treatment of the aforementioned ailments, their prices are very exorbitant. For an average Nigerian patient to effectively treat malaria, he needs nothing less than N10, 000 to N15, 000. This is a disaster in a country where 140 million people are living in poverty.

When this writer sought an explanation from Pharm. (Mrs) Uzoma Ezeoke, executive director (General Duties, Human Resources and Finance), Emzor Pharmaceuticals Limited, on the glaring paradox of NAFDAC’s 50:50 narrative and the lingering inability of Nigerian patients to access affordable medicines, she pointed to a value-chain issue.

Ezeoke said the affordability crisis facing Nigerian patients cannot be resolved simply by expanding local pharmaceutical manufacturing, arguing that attention must also be given to the entire medicine value chain. According to her, manufacturers know the prices at which their products leave the factory, but have limited control over subsequent mark-ups imposed at different levels before the medicines reach consumers.

Ezeoke added that the lack of effective oversight across those levels results in successive price increases, placing additional pressure on patients already struggling with rising healthcare costs. She also pointed to an imbalance between locally manufactured and imported medicines, saying local manufacturers face pressure to address pricing while imported products do not necessarily face the same level of pressure.

Addressing the rising cost of medicines requires the government to look beyond manufacturers and examine the entire supply chain, from production to the final patient. There should be stronger monitoring of medicine prices at every stage, with greater transparency around the mark-ups applied by manufacturers, distributors, wholesalers and pharmacies. If a medicine leaves the factory at a particular price and reaches the patient at a significantly higher price, regulators should be able to identify where and why the increase occurred.

Government should also ensure that locally manufactured and imported medicines are subject to a fair and transparent pricing environment, while reducing the costs faced by local manufacturers through policies that address foreign exchange, electricity, raw materials, machinery, taxes, transportation and access to affordable financing.

The responsibility, therefore, is shared across the entire pharmaceutical value chain, although government must take the lead by providing effective regulation, reliable price intelligence and a competitive environment that protects both patients and manufacturers. Pharmaceutical manufacturers must be transparent about their costs and avoid unjustified price increases, while distributors, wholesalers and pharmacies should ensure that their margins are reasonable and defensible.

At the same time, the government should strengthen competition and regularly monitor the prices of essential medicines to identify excessive or unexplained increases. The goal should not be to force manufacturers to sell medicines below sustainable prices, but to ensure that every stage of the supply chain operates responsibly so that patients are not burdened with unnecessary costs.

Translate healthcare reforms into better patient outcomes, Baale charges pharmacists

0
Prof. Lere Baale

The President and Chairman of the Governing Council of the Nigeria Academy of Pharmacy, Prof. Lere Baale, has challenged pharmacists to take a leading role in transforming Nigeria’s healthcare system, insisting that the country must move beyond impressive policy documents to measurable improvements in patients’ lives.

Baale said Nigeria’s persistent healthcare challenges were largely attributable to fragmented implementation, weak accountability, inadequate financing and poor coordination among institutions, rather than a complete absence of sound policies.

He made the call while delivering the first plenary address at the ongoing 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN), tagged IJELE 2026, at the International Convention Centre, Awka, Anambra State.

Speaking on the topic, “From Policy Promises to Patient Outcomes: Transforming Nigeria’s Healthcare System through Leadership, Accountability, Innovation and Collaboration,” the academy president said the gap between government policy intentions and the actual experiences of citizens remained one of the greatest obstacles to sustainable healthcare delivery.

He identified five major gaps in the country’s healthcare policy implementation framework, including policy design, implementation, coordination, financing and accountability.

According to him, policies are sometimes formulated without sufficient understanding of the realities confronting frontline healthcare providers and patients, while institutions responsible for implementation often lack the resources, authority and capacity required to deliver expected outcomes.

He also noted that federal, state and local institutions, regulators, professional bodies and private-sector organisations frequently pursue similar healthcare objectives without adequate coordination.

He said accountability must also be redefined to focus on whether patients receive better healthcare services, have access to affordable medicines and experience improved health outcomes, rather than merely measuring budgets, meetings and administrative activities.

The professor particularly urged pharmacists to strengthen their professional relevance by taking responsibility for identifying, documenting and reporting medication errors in hospitals and community pharmacies.

He said hospital pharmacists should systematically audit doctors’ prescriptions and document medication errors, with findings presented periodically to medical teams to improve patient safety.

“If we really want to show bigger accountability as pharmacists, we must start not today. We must start yesterday”, he said.

He argued that pharmacists must demonstrate their expertise in medicines through evidence-based interventions that reduce medication-related harm, rather than allowing professional disagreements or commercial interests to undermine their contribution to healthcare delivery.

Baale also called for the integration of community pharmacies into primary healthcare services, proposing a stronger partnership between community pharmacies and the National Primary Health Care Development Agency.

He said Nigeria had approximately 6,000 community pharmacies, which could complement existing primary healthcare facilities and significantly expand access to essential services.

According to him, bringing the two structures together would increase the country’s capacity to provide primary healthcare, particularly preventive services and vaccination, if community pharmacies were appropriately integrated into government programmes.

He said the collaboration would demonstrate the value of public-private partnerships in addressing healthcare delivery gaps.

The academy president further called for a transition from healthcare expenditure to sustainable financing through pooled financing arrangements, broader insurance protection, strategic purchasing and equitable access to essential services.

He warned against poor procurement decisions in hospitals, stressing that pharmacists must be involved in determining the medicines and quantities required to avoid unnecessary expenditure and wastage.

On healthcare delivery, he called for stronger integration of primary, secondary and tertiary healthcare institutions to ensure that patients receive treatment at the appropriate levels.

He observed that minor conditions that could be managed at primary healthcare centres often ended up in teaching hospitals, thereby placing unnecessary pressure on specialist facilities.

He also urged the government and relevant stakeholders to strengthen digital health systems and information sharing to improve referrals, continuity of care and healthcare efficiency.

Baale identified leadership as the missing link between healthcare policy ambitions and actual achievements, insisting that institutions would not transform themselves without responsible leadership and collective commitment.

“The major missing link between ambition and achievement is leadership,” he said.

He described pharmacists as professionals with the training and capacity to contribute beyond medicine dispensing, urging them to become more involved in health economics, policy advocacy, digital health, management, negotiation and strategic decision-making.

He challenged the PSN to prioritise policy execution, sustainable health financing, medicine security, primary healthcare integration, digital transformation, workforce development and accountability as it prepares to mark its centenary in 2027.

Baale said the success of Nigeria’s healthcare system should ultimately be measured by its ability to preserve health, prevent suffering, restore dignity and save lives. “Let the patient become the measure of our success”, he said.

 

 

Stakeholders x-ray how poor implementation undermines healthcare delivery

0

As Budah, Baale, Ahmed call for urgent action

L-R: PCN Registrar, Pharm. Babashehu Ahmed;, Former PSN President Pharm. Yaro Budah; NAPharm President, Prof. Lere Baale and MD, May & Baker Plc, Pharm Patrick Ajah.

Nigeria’s healthcare system must move beyond policy formulation to effective implementation, accountability and stronger pharmaceutical regulation to deliver sustainable outcomes, stakeholders in the pharmaceutical sector have said.

The President and Chairman of the Governing Council of the Nigeria Academy of Pharmacy, Prof. Lere Baale, and the Registrar of the Pharmacy Council of Nigeria (PCN), Pharm. Babashehu Ahmed, made the call at the first plenary session of the ongoing 99th Annual National Conference of the Pharmaceutical Society of Nigeria, tagged IJELE 2026, at the International Convention Centre, Awka, Anambra State.

The session, which examined how policy gaps could be bridged for sustainable healthcare outcomes, was moderated by the Managing Director, May & Baker PLC, Pharm. Patrick Ajah and chaired by former PSN President, Pharm. Yaro Budah.

Speaking on the topic “From Policy Promises to Patient Outcomes: Transforming Nigeria’s Healthcare System through Leadership, Accountability, Innovation and Collaboration”, Prof. Baale said the country’s major challenge was not the absence of good policies but the failure to translate them into improved patient experiences.

“The policy gap is different between what the policy intends, when it was announced, or the document, and what the citizens actually experience”, he said. He identified five interconnected gaps in policy design, implementation, coordination, financing and accountability.

He explained that policies are sometimes developed without sufficient understanding of frontline realities, while institutions responsible for implementation lacked the resources, authority and capacity to deliver.

Baale, who drew from his experience serving on the board of a teaching hospital, said inadequate funding remained a major obstacle, noting that about 60 per cent of the institution’s expenditure went into doctors’ salaries, leaving insufficient resources for other essential needs.

He argued that healthcare accountability should not be measured merely by budgets, meetings and reports but by improvements in patients’ health, access to medicines and the resilience of communities.

Challenging pharmacists to demonstrate their professional value, he urged hospital pharmacists to audit doctors’ prescriptions, document medication errors and present their findings to medical teams periodically.

“If there are clear medication errors, we document it. At the end of the month or quarter, the pharmacist must stand up in the midst of those medical doctors and tell them the medication errors they picked up”, he said.

He also urged community pharmacists to document medication errors and share their findings with doctors in their communities, saying such evidence would strengthen the profession’s contribution to patient safety.

On primary healthcare, Prof. Baale proposed a partnership between the approximately 6,000 community pharmacies and the Primary Health Care Development Agency, arguing that integrating the facilities into primary healthcare activities could expand access to preventive services and vaccination.

He said, “As soon as every community pharmacy can therefore participate in all the activities of primary healthcare, beyond merely selling, they’ll be able to also give free vaccination when the government supplies those items”.

Prof. Baale further called for stronger local pharmaceutical manufacturing, improved supply-chain management, digital health integration and greater involvement of pharmacists in healthcare policy decisions.

In his presentation, titled “Building Stronger Health Systems through Pharmaceutical Governance and Regulation”, Ahmed said effective regulation, transparency and accountability were essential to a functional healthcare system.

He identified the World Health Organisation’s six building blocks of a health system as leadership and governance, competent health workforce, access to quality medicines and medical products, effective service delivery, reliable health information and sustainable financing.

The PCN registrar disclosed that the council released N450 million to Pharmaceutical Inspection Committees and Patent and Proprietary Medicine Committees between January and September 2026 to strengthen regulatory activities.

He, however, expressed concern that illegal pharmaceutical premises continued to operate despite the regulatory structures and funding provided.

“This year alone, we have closed more than 5,000 facilities across 11 states through enforcement activities. This is in an attempt to get the drug distribution system right”, he said.

Giving details of the enforcement exercise, Ahmed said 9,908 facilities were visited between March 29 and October 16, including 1,600 pharmacies and 5,698 patent and proprietary medicine vendor premises.

Ahmed further disclosed that the council had handled about 60 litigations and spent approximately N50 million on the cases in 2026.  The registrar urged state governments to intensify enforcement, commending Lagos, Anambra and Nasarawa for taking steps in that direction.

“Everything does not start and end with the Pharmacy Council, either at the registrar or even at the governing council. It starts with the states”, he said.

The Chairman of the session, Budah, who served as PSN president from 2000 to 2003, said Nigeria had good healthcare policies but continued to struggle with their implementation.

He recalled the society’s role in pushing for the Pharmacy Council Act of 1991 and the establishment of the National Institute for Pharmaceutical Research and Development, urging the current PSN leadership to document these contributions.

Budah also lamented the declining influence of directors of pharmaceutical services in government procurement decisions, warning that their exclusion could lead to inappropriate drug purchases and wastage.

“In the past, I don’t think that any drug sales or transaction happens in any ministry without the director of pharmaceutical services playing this role”, he said.

He further urged pharmacists to expose unethical practices within the profession rather than shield colleagues involved in wrongdoing, stressing that members must take responsibility for cleansing the profession.

Budah also called for continuity in PCN’s operations, expressing concern that the council was frequently disrupted whenever a new government assumed office, allowing regulatory problems to accumulate.

He warned against the spread of misleading health claims on social media, including unsubstantiated claims that certain products could cure cataracts or cleanse internal organs, and challenged regulators and professional bodies to educate the public and counter such misinformation.

Apapa General Hospital targets improved healthcare, upgrades facilities

0

 

Apapa General Hospital targets improved healthcare, upgrades facilities
Dr. Ime Okon

The General Hospital, Apapa, says it is upgrading infrastructure, expanding specialist services and strengthening partnerships to improve healthcare delivery.

The Medical Director, Dr Ime Okon, said this in an interview with the News Agency of Nigeria (NAN) on Tuesday during the hospital’s 62nd anniversary and inauguration of its renovated Dental and Theatre Suites in Apapa, Lagos.

The renovation was funded by The George Charitable Foundation, a philanthropic organisation supporting education and healthcare.

Okon also president of the Lagos Branch of the Medical Women’s Association of Nigeria (MWAN), said the hospital had provided accessible and affordable secondary healthcare to residents of Apapa and neighbouring communities over the years.

She listed its services to include maternal and child healthcare, medical and surgical care, emergency services, dental treatment, preventive healthcare and management of various medical conditions.

According to her, the hospital has also contributed to training healthcare professionals and served as a referral centre, touching thousands of lives over its 62-year history.

“The renovation of these two critical service areas is a major step towards improving the quality and scope of healthcare delivery in our hospital,” she said.

Okon said the renovated Theatre would improve surgical safety, infection prevention and control, workflow and the working environment for patients and healthcare professionals.

She added that the upgraded Dental Suite would provide a more conducive environment for consultations, diagnosis and treatment, while expanding access to dental services.

According to her, the improved facilities would boost patient confidence, reduce referrals to external facilities and strengthen access to quality secondary healthcare.

The medical director said the renovation addressed challenges arising from ageing infrastructure, prolonged use and increasing patient demand.

She expressed appreciation to The George Charitable Foundation, describing its intervention as an example of effective public-private and philanthropic partnership in healthcare development.

Okon said the hospital would sustain the facilities through preventive maintenance, proper equipment management, regular servicing and accountability by the relevant units.

She added that staff training, compliance with standard operating procedures, infection prevention and control, and routine equipment monitoring would be prioritised.

The medical director said the hospital would also strengthen collaboration with development partners, philanthropists, corporate organisations and the newly inaugurated Friends of General Hospital Apapa (FOGHA).

According to her, FOGHA would mobilise community support, resources and expertise to sustain and improve healthcare services.

She said the hospital’s priorities included continuous infrastructure modernisation, acquisition and maintenance of medical and diagnostic equipment, staff development and improved welfare.

Okon added that the hospital would strengthen clinical governance, patient safety, infection prevention and digital transformation through electronic medical records and other digital systems.

She said the hospital also plans to expand specialised medical, surgical, dental, maternal and child healthcare services, alongside preventive care, screening, health education and community outreach.

The medical director said the hospital would deepen partnerships with the Lagos State Government, private sector, philanthropic organisations, professional associations and community stakeholders to improve service delivery.

She described FOGHA as an important initiative, stressing that healthcare development required collective ownership and shared responsibility beyond government efforts.

“I always say that a hospital is not defined merely by its buildings, equipment or number of beds; it is defined by the lives it touches and the quality of care it provides,” she said.

Okon expressed appreciation to the Lagos State Government, The George Charitable Foundation, political, traditional and religious leaders, and other partners for supporting the hospital.

“At 62, we are not just celebrating longevity; we are renewing our promise to serve, heal and save lives,” she said.

(NAN)

FG, PSN deepen push for local drug manufacturing, research

0
FG, PSN deepen push for local drug manufacturing, research
Governor of Anambra State, Prof. Charles Soludo (4th left),PSN President, Pharm. Tanko Ayuba (3rd left), they are flanked by PSN past presidents

Governor of Anambra State, Prof. Charles Soludo (4th left), PSN President, Pharm. Tanko Ayuba (3rd left), flanked by PSN past presidents

The Federal Government has expressed readiness to deepen collaboration with the Pharmaceutical Society of Nigeria (PSN) to expand pharmaceutical services, support local drug manufacturing, enhance research and innovation, and improve healthcare delivery across the country.

The Minister of Health and Social Welfare, Prof. Muhammad Ali Pate, stated this at the opening ceremony of the ongoing 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN), tagged Ijele ’26, in Awka, Anambra State.

Prof. Pate, who was ably represented by the Director of Food and Drugs Services Department in the ministry, Dr Adeola Olufowobi-Yusuf, said the government recognised the critical role of pharmacists in the country’s healthcare system and is committed to creating an enabling environment for the profession to contribute more effectively to national health development.

He said the Federal Government, under the Renewed Hope Agenda, is implementing healthcare reforms that require stronger partnerships with professional bodies such as the PSN to achieve sustainable improvements in healthcare delivery.

“As we continue to implement healthcare reform under the Renewed Hope Agenda, we look forward to deeper collaboration with PSN, investing in pharmaceutical services, advancing research and innovation, promoting local manufacturing, and improving health outcomes for all Nigerians”, he said.

The minister also acknowledged the growing contributions of community pharmacies to primary healthcare delivery, particularly in providing accessible health information, preventive services, referral support and family health interventions.

According to him, the increasing relevance of community pharmacies in the healthcare system underscores the need to promote the responsible use of medicines while strengthening access to quality pharmaceutical services.

Prof. Pate urged pharmacists to work together as a united professional body and partner with the government in addressing the challenges confronting healthcare delivery in Nigeria.

He said the government remained committed to creating an enabling environment that would allow pharmaceutical practitioners to make meaningful contributions to the country’s health sector.

The minister challenged participants at the conference to ensure that the discussions and resolutions reached are translated into practical actions capable of strengthening the healthcare system.

He stressed that the collaboration being advocated should not end with the 99th annual conference but should develop into sustained partnerships and working relationships beyond the event.

“One of the presenters mentioned the collaboration that we should not only leave behind at the conference, but we should move to form a team, to form a collaboration that will go beyond this 99th celebration”, he said.

Pate expressed confidence that the deliberations at the conference would produce practical recommendations for improving Nigeria’s healthcare system, while wishing the pharmacists a successful conference.

Who takes the seat as Ekwunife, Ndukwe jostle for PSN National Secretary?

0

 

Pharm. Ndukwe Uma Ndukwe and Pharm. Kingsley Okwunife

The race for National Secretary of the Pharmaceutical Society of Nigeria (PSN) has continued to gain momentum, with two pharmacists, Kingsley Ekwunife and Ndukwe Uma Ndukwe, intensifying their campaigns ahead of Friday’s election at the society’s 99th Annual National Conference in Awka, Anambra State.

The contest, which has drawn considerable interest among delegates attending the conference, will see one of the two aspirants emerge as the society’s next National Secretary, succeeding the incumbent, Pharmacist Gafar Madehin.

Both candidates have been actively canvassing for support among members of the society, using the ongoing conference as an opportunity to reach out to delegates and present their respective aspirations for the position.

The election is scheduled to be held on Friday, 6 November, following the society’s Annual General Meeting (AGM), where members are expected to decide who takes over the administrative position.

The intensity of the contest is already evident across the conference venue and other locations hosting delegates. As of press time, campaign posters bearing the photographs and messages of both candidates were conspicuously displayed at the entrance and virtually every nook and cranny of the International Convention Centre, Awka, venue of the conference.

The campaign materials were also visible at the entrances of some hotels accommodating delegates, a move by both contenders to attract the attention and secure the support of delegates ahead of the election.

The position is particularly important to the administration of the PSN, as the National Secretary plays a central role in the society’s coordination, documentation, communication and implementation of decisions reached by its leadership. The outcome of Friday’s election is therefore expected to determine who will assume responsibility for the society’s secretariat and help drive its administrative activities during the next tenure.

The contest comes at a significant period for the PSN, which is preparing to celebrate its centenary in 2027, having been established in 1927.

Pharm. Ekwunife hails from Ebenebe in Anambra State and has held many positions in organised pharmacy activities, including Vice-Chairman of the West African Postgraduate College of Pharmacists, Nigeria; member of the planning committee of the 2026 PSN’s 99th Annual National Conference; and one-time Social Secretary of PSN Lagos State Chapter. He also serves as the deputy director of Pharmacy at the National Orthopaedic Hospital, Igbobi, Lagos.

Pharm. Ndukwe, on the other hand, has extensive leadership experience across various pharmaceutical bodies. He has served as Assistant National Secretary for both the PSN and ACPN, National PRO for the Association of Public Health Physicians of Nigeria (APHPN) and Editorial Board Secretary for the FIP African Pharmacists Forum.

 

Adelusi-Adeluyi, Soludo, others charge pharmacists on unity, fight against fake drugs

0

 

Adelusi-Adeluyi, Soludo, others charge pharmacists on unity, fight against fake drugs
The keynote speaker Dr Bernard Doro (middle) with his award presented to him by Pharm Ahmed Yakasai alongside PSN president Tanko Ayuba and other past presidents

 

…As over 2000 pharmacists hit Awka for 99th PSN Conference

Pharmacists have been charged to strive to ensure greater unity, stronger collaboration and professional accountability so as to tackle the circulation of fake and substandard medicines and strengthen Nigeria’s healthcare system.

This was the dominant call at the opening ceremony of the ongoing 99th Annual National Conference of the Pharmaceutical Society of Nigeria (PSN) on Tuesday in Awka, Anambra State. The Conference Planning Committee chairman, Pharm. Derrick Osondu told Pharmanewsonline on Tuesday that nearly 3000 pharmacists are already in Awka for the event and more pharmacists are still coming.

In their separate remarks, the speakers, including former Minister of Health, Prince Julius Adelusi-Adeluyi; Anambra State Governor, Prof. Chukwuma Soludo; Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye; and Minister of Humanitarian Affairs and Poverty Alleviation, Dr Bernard Doro, called for a united and coordinated approach to addressing challenges confronting the pharmaceutical profession and the nation’s healthcare delivery system.

The theme of the 99th conference tagged Ijele ’26, held at the International Convention Centre, Awka, is “One Health, One Pharmacy: Bridging Knowledge, Practice and Policy for National Impact”.

Prince Adelusi-Adeluyi, who is chairman of the College of Past Presidents of the PSN, said the profession could only achieve a profound and enduring impact on the nation if pharmacists embraced unity, teamwork and a shared commitment to addressing challenges confronting the profession.

“Teamwork is the foundation of success”, he said, adding that pharmacists must walk together more sincerely to build a profession that would be more respected, robust, reliable and recognised within and outside the healthcare sector.

Similarly, Prof. Soludo urged pharmacists to strengthen professional accountability and collaborate with the Anambra State Government in its efforts to position the state as Nigeria’s pharmaceutical hub.

The governor, who described Anambra as Nigeria’s pharmaceutical capital, said pharmacists had fundamental contributions to make to a productive and sustainable healthcare ecosystem.

He highlighted his administration’s investments in healthcare infrastructure, including the construction, renovation and upgrading of about 326 primary healthcare centres, the recruitment of more than 1,500 healthcare professionals and the establishment of a state quality assurance laboratory to ensure the safety and quality of medicines supplied to public health facilities.

He also disclosed that the state was developing a coordinated pharmaceutical wholesale centre, alongside plans for a pharmaceutical manufacturing plant, to strengthen medicine distribution and local production.

However, Soludo challenged the PSN to look inward and address professional misconduct, particularly the practice of pharmacists lending their licences to individuals operating medicine outlets without their physical presence or professional supervision.

He said such practices undermined public confidence in the profession and made it difficult for regulatory authorities to effectively eliminate fake and substandard medicines.

He urged the PSN to strengthen its internal monitoring and disciplinary mechanisms, insisting that pharmacists who provide cover for illegal medicine businesses should also be held accountable.

“When NAFDAC raids any shop that we get one, we must also get the name and licence of the pharmacist who is covering the misconduct. We cannot just punish the dealer”, Prof. Soludo said.

The keynote speaker, Dr Doro emphasised the need for pharmacists to move beyond professional divisions and become more actively involved in national policy formulation, particularly in addressing medicine access, poverty and public health emergencies.

He said the theme of the conference reflected the need to integrate pharmaceutical knowledge, professional practice and government policy, warning that fragmentation within the profession and the wider healthcare system could undermine national development.

Commenting on the seeming division among pharmacists, Dr Doro said “Sometimes, we behave like separate villages sharing the same name. The industrialist does not talk to the hospital pharmacist. The academic writes papers the regulator never reads. The community pharmacist sees the problem first but nobody asks him”.

Dr Doro, who is also a pharmacist, argued that pharmacists must speak with one voice and ensure that their professional knowledge and evidence from daily practice inform government decisions.

The minister also called for the integration of pharmaceutical services into humanitarian interventions, particularly in displacement camps and underserved communities, where access to essential medicines and professional healthcare services remained critical.

He proposed five areas of collaboration between the PSN and his ministry, including establishing pharmaceutical care in humanitarian response programmes, using community pharmacies to strengthen disease surveillance, tackling antimicrobial resistance through collaboration with agricultural and veterinary stakeholders, linking local pharmaceutical manufacturing to employment and poverty reduction, and producing policy briefs to support evidence-based government decisions.

On antimicrobial resistance, Doro warned that the inappropriate use of antibiotics in farms, markets and healthcare facilities posed a serious threat to public health, stressing that the problem could not be addressed through hospital interventions alone.

Meanwhile, the NAFDAC DG, Prof. Adeyeye, reaffirmed NAFDAC’s commitment to strengthening regulatory collaboration with the pharmacy profession to protect Nigerians from unsafe medicines.

The DG who was ably represented by the Director of Narcotics and Controlled Substances, Dr Rametu Omamegbe Momodu said the agency remained committed to quality, safety and public health, noting that Nigeria had retained the World Health Organisation’s Maturity Level 3 status for the regulation of medicines and vaccines.

The NAFDAC boss called on pharmacists to take responsibility for safeguarding the medicine supply chain through responsible dispensing, patient counselling, antimicrobial stewardship and pharmacovigilance.

She warned that falsified and substandard medical products could cause treatment failure, antimicrobial resistance and death, insisting that their circulation must not be tolerated.

“Every pharmacist and, in fact, all Nigerians are called to be vigilant and guardians of the supply chain”, she said.

Prof. Adeyeye also called for stronger collaboration between NAFDAC and other relevant agencies and bodies on vaccine safety, antimicrobial stewardship, professional education and local pharmaceutical manufacturing.

The 99th PSN conference, which commenced with a walk and welcome cocktail, on Monday, 2 November brought together pharmacists, pharmaceutical industry stakeholders, academics, policymakers and healthcare professionals including the past presidents of the society.

The conference will hit its climax on Friday with an annual general meeting, election of National secretary and closing banquet later in the night.

Ayuba’s two years as PSN president draw praise, criticism

0

– As stakeholders highlight unresolved issues, pending campaign promises

Ayuba’s two years as PSN president draw praise, criticism
Pharm. (Dr) Joel Adagadzu and Pharm. Anthony Oyawole

The performance of the President of the Pharmaceutical Society of Nigeria (PSN), Pharm. Tanko Ayuba, has come under scrutiny as stakeholders and members assess his record during the first two years of his three-year tenure. While some have commended his administration, others have given him a low rating, urging him to fulfil his campaign promises, resolve lingering crises among the Society’s technical groups and develop a concrete economic survival plan for community pharmacists, among other priorities.

With one year remaining in his tenure, stakeholders have also called for the full implementation of the Pharmacists’ Consultancy Cadre across federal and state hospitals, support for the implementation of approved salary adjustments for pharmacists under the Joint Health Sector Unions (JOHESU) framework, and the prompt implementation of actionable recommendations from committees established by the PSN.

In separate interviews with Pharmanews, two former presidential aspirants, Pharm. Anthony Oyawole and Dr Joel Adagadzu, offered their assessments of Ayuba’s performance and urged him to address outstanding issues before his tenure expires.

Commendable reforms

Pharm. Oyawole commended Ayuba’s performance, describing his administration as reform-focused, welfare-driven and defensive of the profession’s regulatory interests. He nevertheless outlined several priorities for the president to address before the end of his tenure.

These include implementing the Pharmacists’ Consultancy Cadre across the federation, improving the economic prospects of community pharmacists and strengthening relationships among the PSN and its technical groups, which include the Association of Community Pharmacists of Nigeria (ACPN), Association of Industrial Pharmacists of Nigeria (NAIP), Association of Hospital and Administrative Pharmacists of Nigeria (AHAPN) and Young Pharmacists Group (YPG).

Recalling the circumstances in which Ayuba assumed office on 9 November 2024, Oyawole said the profession was grappling with three major pressures: the migration of pharmacists, with more than 8,200 reportedly having failed to renew their licences over five years; threats to the autonomy of the Pharmacy Council of Nigeria (PCN) through amendment bills before the National Assembly; and a gap in the pharmaceutical market following the exit of GSK, Sanofi and other multinational pharmaceutical companies.

He described Ayuba’s response to these challenges as methodical rather than populist.

According to Oyawole, the president’s achievements during his first two years include efforts to redefine the pharmacy workforce and reform education, defend the PCN’s regulatory authority, secure welfare gains through the JOHESU/AHPA alliance and strengthen pharmacy’s role in public health.

“This administration’s biggest ideological win is clarity on the workforce. At the 98th Annual Conference in Kano  (DABO 2025), themed ‘Defining a New Pharma Workforce for Nigeria”, he declared Pharm.D as the minimum entry qualification and moved decisively to end the controversial Pharmacy Technologist cadre.

“Following the MoU signed on 17 April, 2025, between the PCN, Federal Ministry of Health and NBTE, training of Pharmacy Technologists was formally discontinued nationwide, aligning Nigeria with global best practice of having only pharmacists and pharmacy technicians,” Oyawole said.

He added: “Under his watch, PSN and PCN secured the Federal High Court ruling in Calabar on October 29, 2025, affirming PCN’s sole authority to regulate veterinary drugs, ending the long dispute with the Veterinary Council of Nigeria. He has also been the most vocal defender against attempts to amend pharmacy laws to reduce professional representation on the PCN Council, correctly reminding government that pharmacy is the only health profession on the Exclusive Legislative List.”

Oyawole also cited the payment of 25–35 per cent of outstanding CONHESS arrears, a four per cent call-duty allowance for Pharm.D holders, the inclusion of Pharm.D and consultant pharmacists in the Integrated Personnel and Payroll Information System (IPPIS), centralised internship placement, and approval of a new retirement age of 65 for pharmacists and 70 for consultant pharmacists.

Disputable success

On his part, Dr Adagadzu gave the PSN president a low rating, saying he could not identify any significant achievement. He attributed what he considered the administration’s poor performance partly to the domestic accident Ayuba survived shortly after his inauguration, which left him with severe injuries and limited his ability to function effectively in office.

“As far as I am concerned, having read about some of the recorded achievements of the current PSN president, I am unable to lay a finger on any standout achievement he recorded in the past two years. This could be due to the unfortunate injury he sustained shortly after his inauguration as president, which greatly affected his capacity to be fully in control, making it virtually difficult for him to oversee his duties with utmost diligence. Thankfully, there are clear indications that he is on his way to full recovery, and I join other well-meaning colleagues in praying for his total healing,” Adagadzu said.

The former chairman of the BOF-PSN urged Ayuba to fulfil the promises he made to pharmacists during his campaign, arguing that these commitments are central to his election. He also called on the president and his cabinet to undertake an honest appraisal of their performance.

“The PSN president was elected because of his promises to pharmacists. I therefore urge him and his team to sit down and review his performance in the past two years against the strength of those promises and identify existing gaps so that, in his third and final year, he can make up for or improve on whatever performance he has been able to achieve so far.”

During his presidential campaign, Ayuba envisioned a PSN whose members would be valued, well-paid, well-organised and highly motivated healthcare professionals. He also pledged to strengthen pharmacists’ accessibility to the public and their role in promoting the rational use of safe, effective and affordable medicines, pharmaceutical care, public health and improved quality of life.

His campaign priorities included leveraging digital technology to strengthen pharmacists’ capacity, pursuing advocacy and legal measures to enforce existing regulations, tackling disorder in drug distribution and fostering a professional environment that supports pharmacists. He also promised to consolidate the society’s progress, promote favourable policies and position community pharmacies as healthcare hubs.

Accordingly, Adagadzu urged Ayuba to use his remaining year in office to address unresolved matters and demonstrate progress towards fulfilling his campaign promises.

“In his final year, I expect the PSN president to address lingering crises rocking some of the technical groups of the PSN, such as the ACPN and YPG, towards achieving unity or oneness among pharmacists; be fully in charge as the Commander-in-Chief of the PSN with minimal distractions; address his unfulfilled campaign promises, especially the need to support the pharmaceutical industry to increase its local production capacity in Nigeria towards achieving medicine security; confront the poor uptake of consultant pharmacists in federal and state health institutions and facilities; ensure the prompt implementation of actionable committee reports; and firmly oversee the centenary celebrations lined up for 2027, given their potential to increase the visibility of pharmacists,” he said.

Assessing the organisation of the PSN’s annual conference in recent years, Adagadzu expressed concern about technical groups holding their annual general meetings (AGMs) during the conference, arguing that this could distract from the event’s core programme. He called for a review of the arrangement ahead of this year’s conference.

He also lamented the absence of the society’s usual town hall meetings and annual general meetings, while criticising noisy and disorderly election campaigns that, he said, had overshadowed the conference’s main activities.

“Elections in PSN are witnessing the ploys employed in national elections, which are inimical to the professional cohesion once cherished by delegates. The majority of delegates no longer participate in sightseeing tours, for reasons the PSN leadership must look into. Transportation of delegates from hotels to conference venues is becoming quite challenging. More attention needs to be paid to some of these challenges to make PSN conferences the best they can be,” he said.

Conference expectations

Oyawole meanwhile said this year’s conference comes with high expectations and urged Ayuba and his team to ensure effective planning and execution. His recommendations include early communication, efficient logistics, better time management, affordable registration and accommodation, adequate food and welfare arrangements, high-quality speakers and presentations, evidence-based discussions, and opportunities for professional and business networking.

“We need speakers who can deliver evidence, not just titles,” he said. “For the theme ‘One Health, One Pharmacy’, we expect the Director-General of the NCDC, the NAFDAC Director-General, the PCN Registrar, the PVAC Coordinator, the WHO Nigeria Representative, and leaders from the veterinary and environmental sectors — not just pharmacy insiders.

“Registration should be fully digital, with QR-code badges and no queues. There should be partnerships with hotels to secure negotiated rates, shuttle buses, and clear signage at the venue. We have done this well in Kano (DABO 2025) and we should improve on it,” he advised.

Why early screening is Nigeria’s most underused medicine

0
Why early screening is Nigeria’s most underused medicine
Pharm. Sesan Kareem

 

Nigeria now carries the highest cancer burden in Africa. Cancer deaths in this country already exceed deaths from tuberculosis, malaria, and HIV combined. For breast cancer alone, 79 per cent of Nigerian women present with locally advanced or metastatic disease, and only 28 percent survive five years. Compare that to settings where early detection is routine, and five-year survival climbs above 85 percent. The medicines are not meaningfully different. The timing is.

That gap, the one between what we die from and what we could have survived, is the clearest, most actionable public health failure we have. And it is almost entirely a screening problem.

 

The shape of a preventable death

Non-communicable diseases now account for 29 percent of all deaths in Nigeria, roughly 447,800 lives every year. The Ministry of Health estimates that most of these deaths occur between the ages of 30 and 70. These are not elderly Nigerians dying of old age. These are breadwinners, mothers, teachers, pharmacists, people who should have had another two or three decades.

The quiet killers are familiar: hypertension, diabetes, breast cancer, cervical cancer, prostate cancer, chronic kidney disease, sickle cell complications, hepatitis-driven liver cancer. Every one of them is screen-able. Most are treatable when caught early. Almost all become unaffordable, unbearable, or un-survivable when caught late.

The cervical cancer data makes the point painfully. Over half of Nigerian women diagnosed with cervical cancer present at stages III or IV. The vaccine exists. The screening test costs less than a tank of fuel. The disease, caught early, is largely curable. Yet it kills about 8,000 Nigerian women every year, most of them in their prime.

This is not a treatment failure. It is a detection failure.

The economics of catching it early

There is a reason insurers in mature health systems pay for screening without blinking. A mammogram costs a fraction of chemotherapy. An HbA1c test costs a fraction of a diabetic foot amputation. A blood pressure reading costs almost nothing compared to a stroke rehabilitation bill.

In Nigeria, where roughly 70 per cent of healthcare is paid out of pocket, the economics are even more stark. A family that could have absorbed a N15,000 screening cost twelve months earlier will often face a N15 million treatment bill, sell property, drain pensions, and still bury the patient. The financial violence of late diagnosis is one of the most under-discussed drivers of poverty in this country.

If we are serious about universal health coverage, we cannot build it on a treatment-first model. The arithmetic does not work. The only affordable health system is one that invests heavily in the cheap, boring, upstream interventions that stop expensive illness from happening in the first place.

Where pharmacists come in

Here is the uncomfortable truth for our profession: pharmacies are the most accessible health touchpoint in Nigeria, and we have systematically underused that position.

The average Nigerian visits a pharmacy five to seven times more often than they visit a doctor. Every one of those visits is a missed screening opportunity. A pharmacist checking blood pressure during a routine antimalarial purchase has prevented more strokes than most of us will ever know. A pharmacist flagging a persistent cough, an unexplained weight loss, a change in bowel habits, or an abnormal lump has pulled patients back from timelines they did not know they were on.

Community pharmacy must evolve from a dispensing counter into a frontline detection network. That means normalising blood pressure, blood sugar, BMI, and waist circumference checks for every adult who walks in. It means training staff to recognise red flags and refer. It means partnering with laboratories, hospitals, and digital health platforms so a flagged patient actually completes the diagnostic journey rather than disappearing after the referral.

At HubPharm Africa, early detection is embedded into our chronic condition infrastructure. Our 10 clinical programmes, from Heart Health Access to Cancer Access to Diabetes and Endocrinology Access, are designed around the premise that no patient should die from a disease we could have caught. Our 3rd Annual Free Health Screening this year will put thousands of Nigerians through a package of checks they would otherwise have skipped. It is one of the most impactful things we do, and it costs less than many of our marketing line items.

 

Sesan Kareem is the founder and president of HubPharm Africa, a licensed pharmacy and chronic condition management platform. Hubpharm is recognised as ECOWAS startup of the year 2026 for its innovation in chronic care management.

N10bn health security fund not only for Ebola preparedness- NCDC

0
 N10bn health security fund not only for Ebola preparedness- NCDC
An Image of NCDC Logo

The Nigeria Centre for Disease Control and Prevention (NCDC) says the Federal Government’s release of N10 billion is intended to strengthen the country’s overall health security system, not solely for Ebola preparedness amid public debate.

The Director-General of NCDC, Dr Jide Idris, said this in a statement issued in Abuja on Monday, clarifying concerns surrounding the allocation amid public discussions about Nigeria’s Ebola response.

Idris explained that the funding request covered prevention, preparedness, early detection and rapid response to several public health threats, including Ebola, Lassa fever, cholera and meningitis, among other diseases.

Others include diphtheria, measles, Mpox and antimicrobial resistance, which he said had historically contributed significantly to illness and deaths across the country, placing considerable pressure on Nigeria’s healthcare system.

He clarified that the N10 billion was released directly to NCDC, not the Presidential Task Force on Ebola Virus Disease, chaired by the Chief of Staff to the President.

He said that the task force was established primarily to coordinate the national response, while the allocation was intended to address wider national health security needs beyond Ebola preparedness.

Idris said the N10 billion remained inadequate, considering the scale of investment required to strengthen Nigeria’s capacity to prevent, detect and respond effectively to public health emergencies nationwide.

He explained that Nigeria’s National Action Plan for Health Security (NAPHS) 2.0, covering 2025 to 2029, required approximately N522 billion for implementation over five years across multiple sectors.

The plan, he said, translated to an average annual requirement of N104.4 billion, although not all its activities were funded through NCDC or its available government allocations.

He said that the N10 billion represented about two per cent of the plan’s average annual cost, underscoring the funding gap confronting Nigeria’s health security system and preparedness efforts.

Idris said NAPHS 2.0 adopted a multisectoral, One Health approach, bringing together government ministries, departments and agencies, development partners, civil society organisations and other relevant stakeholders nationwide.

He explained that the plan followed the expiration of Nigeria’s first National Action Plan for Health Security, under which inadequate funding had remained a major implementation constraint for years.

The NCDC director-general said Nigeria needed sustainable domestic and external funding to strengthen preparedness and prevent outbreaks from escalating into national emergencies, threatening lives and livelihoods across communities.

He urged policymakers, the media and development partners to support adequate and accountable investment in NCDC and the country’s wider health security system to improve emergency preparedness.

Idris said Nigeria had responded to its first imported Ebola case with vigilance and precaution, emphasising that the situation did not warrant public panic or unnecessary alarm.

He said the Bundibugyo Ebola case was confirmed in NCDC’s laboratory on Oct. 20, 2026, within 24 hours of receiving the alert in Abuja, demonstrating rapid laboratory response.

He added that all identified contacts were under daily monitoring, while Nigeria currently had no active Ebola case following the management of the imported infection and associated response measures.

However, he said surveillance would continue until the last identified contact completed the mandatory 21-day monitoring period without developing symptoms or any new case emerging during surveillance.

Idris emphasised that the country was not yet out of the woods, assuring Nigerians that NCDC would continue providing updates on the evolving situation through official communication channels.

He said the current epidemiological situation did not warrant postponing elections, banning campaigns or mass gatherings, or imposing travel restrictions on Nigerians and international visitors at present.

According to him, NCDC has not recommended such measures but has developed technical guidelines for organisers of mass gatherings to ensure compliance with infection prevention and control protocols.

He said events could proceed safely with strict adherence to established safety measures, adding that the agency would revise its recommendations if new evidence warranted changes in guidance.

Idris urged Nigerians to verify information through NCDC’s official communication channels before sharing reports, warning that rumours and misinformation could undermine public trust and response efforts during outbreaks.

On health security financing, he said NCDC’s allocation increased from N4 billion in 2024 to N7 billion in 2025, followed by a N5 billion intervention fund.

He added that the 2026 Appropriation provided N22 billion, while President Bola Tinubu approved an additional N10 billion emergency intervention fund in June 2026 to strengthen preparedness.

The NCDC chief said the additional funding was requested to address epidemic-prone diseases generally, rather than Ebola alone, and complement resources already mobilised from government and development partners.

He said the Global Preparedness Monitoring Board estimated that countries required between one and two dollars per person annually for acceptable epidemic preparedness and effective emergency response capacity.

Based on Nigeria’s estimated population of 240 million, Idris said the country required between 240 million and 480 million dollars annually to achieve adequate preparedness against public health threats.

He called for sustained investment from federal and state governments, as well as development partners, to close the funding gap and strengthen national health security across all sectors.

Idris said health security was one of the four pillars of the Nigeria Health Sector Renewal Investment Initiative, describing sustained financing as essential to achieving its objectives nationwide.

He maintained that preventing outbreaks, deaths and economic disruptions required deliberate investment, urging Nigerians to regard health security as a national responsibility requiring collective commitment and sustained support.

The NCDC director-general assured Nigerians of transparency, accountability and prudent utilisation of resources entrusted to the agency, reaffirming its commitment to protecting public health across the country.
(NAN)

Imo University, Robotic Academy, target training 500 surgeons in 2 years

0

 

Imo University, Robotic Academy, target training 500 surgeons in 2 years

Imo State University (IMSU) has established a robotic surgery academy in partnership with the Imo Robotic Centre, targeting to train 500 surgeons and other surgical professionals within two years.

Prof. Kingsley Ekwueme, consultant urologist, disclosed this in an interview with the News Agency of Nigeria (NAN).

Ekwueme, recently appointed professor of Robotic Surgery at the IMSU, described the initiative as Africa’s first dedicated robotic surgery academy, with department located within the institution’s premises.

He said the partnership was established in August 2026, following a meeting between the university and its partners.

“We have successfully performed the first surgery in the region in August.

“We followed up with multiple robotic surgeries at the Imo Robotic Centre, where many patients are already benefiting from this state-of-the-art technology, now available for the first time in southeast Nigeria.

“We have also partnered with Imo State University, following a successful meeting on the Aug. 18 and launched the robotic surgery academy at the university.

“It is important for me and for the academic proficiency at Imo State University, that any erroneous claim of the first robotic surgery academy is debunked and the records are straight,’’ he said.

According to Ekwueme, currently in Imo, the Imo Robotic Centre is delivering state-of-the-art surgery in the state.

“We have performed several surgeries successfully and patients are benefiting.

“Imo State University has partnered with the Imo Robotic Centre for the first robotic academy. It is important that I refer everyone to the university publication of Aug. 19, confirming the set-up of that robotic academy.

“A Memorandum of Understanding (MoU) was also subsequently signed and a departmental building has been assigned for the establishment of the robotic academy,” he explained.

The surgeon emphasised that building human expertise to treat patients domestically, was key to stopping health-related capital flight.

“We are not only training surgeons, but we are also training the whole surgical team.

“This is very important because we want to train a team to be able to deliver safe and effective robotic surgery at their own local centre,” Ekwueme said.

He added that the academy would support participating hospitals with equipment procurement and installation to decentralise access nationwide.

Ekwueme, Clinical Lead for Urology in North Wales at Glan Clwyd Hospital, UK, commended Gov. Hope Uzodimma’s administration for supporting the initiative.

He stressed that local access ensured Nigerians no longer needed to travel abroad or out of the region for complex procedures.
Nigerian political analysis

“We have bridged the gap. So, nobody needs to travel beyond leaving your house and driving a few minutes down the road to have your surgery,” he said.

“Plans are also progressing to complete an adjacent oncology centre and medical institute for specialised cancer diagnostic services.

“We are also in the process of finalising the oncology centre that is adjacent to the robotic centre that will have state-of-the-art diagnostic and oncology services.

“A medical institute is being created between the Imo State Government and the Imo Robotic Centre. We are also in the process of finalising the medical institute that will have state-of-the-art diagnostic and oncology services.

“I thank the vice chancellor of the Imo State university for the honour of the appointment as professor of Robotic Surgery,” he said.

Ekwueme, a Royal College of Surgeons of Edinburgh faculty member, noted that his team had performed over 145 robotic procedures in Africa.

“I believe that the recognition by the university is just icing on the cake,” he said.

“In 10 years, I see every Nigerian having access to robotic surgery anywhere in Nigeria.

“I see a Nigeria where brain drain would be significantly less.
Nigerian political analysis

“I dare to predict there is going to be a reversal of brain drain. A reversal back to Nigeria,” he said.

He stated that procedures like prostate, kidney, fibroid, hysterectomy, bowel and gallbladder surgeries could now be performed locally.

Explaining the clinical applications of robotic surgery, Ekwueme said the technology could be used across several specialties, including urology, gynaecology, general surgery and selected cardiac procedures.

He listed prostate and kidney operations, fibroid removal, hysterectomy, ovarian procedures, bowel cancer surgery and selected gallbladder operations, among procedures that could be performed with robotic assistance.

According to him, robotic systems provide surgeons with three-dimensional magnified views of the operating field and instruments that enable precise movements in confined spaces.

These capabilities, he said, could help reduce surgical trauma, blood loss and recovery time in appropriately selected patients.

“The advantages of robotic surgery cannot be overstated,” he said.

He contrasted the approach with conventional open surgery, which often required larger incisions and could involve longer hospital stays and recovery periods.

However, Ekwueme emphasised that acquiring robotic equipment alone would not guarantee good outcomes, stressing the importance of proper training and surgical proficiency.

“The surgeon has to also be proficient in the use of the robotic machine. And that is where this training, that we are creating, becomes important,” he said.

He urged the Federal Government to support the initiative through tax waivers on equipment imports, to lower out-of-pocket patient costs.

“We know how to acquire affordable robotic systems. I will advise any public institution to come to train with us.

”We will help them to acquire robots, without a doubt,” he said.
He expressed optimism that training 500 professionals through IMSU certification would reverse medical tourism and revolutionise African healthcare.

“I seriously believe that a medical revolution is happening in Nigeria at the moment.”

“I think that the world must pay attention to that, you know, because we are doing some great things here,” Ekwueme said.
He said the academy’s emphasis on training entire surgical teams was intended to ensure that hospitals could use the technology safely and effectively, rather than depend solely on the availability of equipment.

Ekwueme also said his team had performed what he described as the first gynaecological robotic surgery in West Africa through its programme at the prostate clinic, adding that the patient was discharged on the same day.
(NAN)

A patient taking erythromycin develops an increased plasma concentration of warfarin,

5

PANS QUIZ

1. A patient taking erythromycin develops an increased plasma concentration of warfarin, resulting in an elevated INR and bleeding risk. Which pharmacokinetic mechanism best explains this interaction?

A. Reduced gastrointestinal absorption
B. Inhibition of hepatic drug-metabolising enzymes
C. Induction of CYP3A4 enzymes
D. Increased renal tubular secretion

2. A weakly basic drug is formulated as an enteric-coated tablet. If the coating fails prematurely in the acidic environment of the stomach, what is the most likely formulation-related consequence?
A. Reduced drug ionisation and increased lipid solubility
B. Increased drug ionisation and possible reduced absorption
C. Immediate conversion of the drug into its active metabolite
D. Increased protection of the drug from gastric degradation

NAFDAC strengthens drug regulation across Africa

0
NAFDAC strengthens drug regulation across Africa
NAFDAC, Prof. Mojisola Adeyeye.

The Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, has highlighted Nigeria’s regulatory reforms as an example of how African countries can build stronger and more reliable medicines regulatory systems.

Adeyeye made this known while speaking at the Global Health Perspectives series organised by the Takemi Program in International Health at Harvard T.H. Chan School of Public Health.

The DG disclosed that the agency has made some improvement since 2017, particularly from below the World Health Organisation (WHO) Maturity Level 1 to Level 3. She also identified attaining Level 4 and becoming a WHO-Listed Authority as the agency’s next targets.

The NAFDAC boss attributed the agency’s transformation to five major areas of reform, including improved governance, stronger scientific and quality capabilities, better monitoring of medical products, digitalisation of regulatory processes and partnerships with industry and development organisations.
She listed some of the agency’s achievements to include obtaining ISO 9001 certification, securing WHO prequalification for its laboratory, expanding laboratory capacity and strengthening enforcement activities.

Adeyeye also disclosed that about 90 per cent of NAFDAC’s regulatory processes have been digitised to improve efficiency and accountability.

She stressed the need for strong leadership, financial accountability, evidence-based decisions and international collaboration in tackling the circulation of substandard and falsified medical products.

The Director-General further emphasised the importance of supporting local pharmaceutical manufacturers while ensuring that the quality and safety of medicines are not compromised.

The lecture highlighted the role of sustained institutional reforms, investment in science and cooperation among regulatory agencies in improving access to safe and effective medical products across Africa.